Solving
Kids'
Cancer
UK

Annual Report & Accounts

2023/2024

Alec

WHO'S ON OUR COVER?
At just 19 weeks old, Alec was diagnosed with intermediate risk neuroblastoma. After four rounds of chemotherapy and surgery to remove his primary tumour Alec had no evidence of disease in February 2017.

Alec has struggled with late effects caused by treatment, 3 corrective surgeries with one more due and Horner Syndrome which has affected his temperature control from the nerve damage, muscle weakness and trauma.

In May 2024 Alec celebrated being in remission for over seven years.

Our vision

Solving Kids' Cancer UK's vision is a future where no child dies of the childhood cancer neuroblastoma or suffers due to the treatment they receive.

Our mission

Helping those affected by neuroblastoma, an often aggressive and deadly childhood cancer, by:

- Initiating and funding best-in-class clinical research
- Providing hope, information and support to families throughout their cancer journey
- Raising awareness of childhood cancer, advocating and campaigning for positive change.

Contents

Our year

Every two weeks a child in the UK with neuroblastoma dies.
Help us to change this outcome.

We are a small but mighty parent-led charity with children firmly at our heart. We are striving for better outcomes for children and families affected by neuroblastoma, both now and in the future. In every conversation, we amplify their voice and ensure their needs are at the heart of all we do.

We will not stop until children with neuroblastoma, in the UK and beyond, have access to the treatments they need, when they need it, as close to home as possible.

Over the last year, we have:

- Delivered the second year of our ambitious strategy, introducing our new brand and strengthening our networks and infrastructure.
- Launched our public affairs strategy through the Unlocking Hope campaign.
- Extended funding for the MiNivAn clinical trial, maintaining treatment options for children in the UK and funded a new molecular radiotherapy trial to open afterwards (MINT) for children who currently have no well-defined therapeutic options.
- Welcomed over 360 participants from 29 countries to our fourth Neuroblastoma Parent Global Symposium, including a new psychosocial programme of seminars and peer support sessions.
- Delivered our first co-facilitated post treatment and bereavement coaching programmes alongside Life After Cancer and devised and began to roll out our first SKC-run coaching programme for parents.
- Reached more families of children diagnosed with neuroblastoma at an earlier point, providing 47 Big Love Fund grants to families and 49 Care & Connect Support Bags to children.
- We were supported by some amazing partners, individuals and organisations to enable events including our Carol Concert, our charity film premiere, the ISBA Solicitors Ball and in partnership with SpecialEffect the wonderful British Racing Greats event.
- Funded five Research Grants including concluding the $2m ACTION grant call for an innovative approach to accelerating clinical trials and evaluating novel therapies, renewed our Senior Neuroblastoma Clinical Trials Coordinator role at the Clinical Trials Unit in Birmingham and supported the BIOPORTAL project to improve neuroblastoma understanding.

Welcome

Introduction from our Chair of Trustees

Welcome to our annual report for 2023/24, showcasing Solving Kids' Cancer UK's unwavering commitment to children and families affected by neuroblastoma. In these pages you'll read about the work we've been doing over the past twelve months to directly improve the lives of children with neuroblastoma and their families and learn more about our aims for the forthcoming year.

Our efforts are guided by our strategy, as outlined on pages 8 and 9, with impact measured by how effectively we deliver against objectives in our three strategic pillars. We serve the needs of individual children through our unique support service, and work on behalf of all children in our research, advocacy and awareness initiatives. Central to such endeavours is our newly-developed policy and public affairs work, which is gathering momentum as we address the barriers holding back delivery of clinical trials for children with cancer in the UK that are critical to improving survival and quality of life.

Underpinning everything Solving Kids' Cancer UK does is governance, finance, operations, and fundraising. Areas often less visible, but nonetheless vital to ensuring effective delivery of services in support of our mission.

Our Trustees are committed volunteers dedicating their time to set strategic direction, provide governance and oversight of all activities, and assess performance against aims and objectives. The Board's role is to provide the best possible stewardship to maintain the charity's continued good health and sustainability. I'm delighted we've appointed several new Trustees to join us over the coming year, to bring new skills and fresh perspectives.

Finance and operations are critical to the smooth running of the organisation and play a pivotal role in delivering for children and families. An example being our research collaborations with multiple funding partners and participating research institutions, requiring expert management of agreements and money flows without which we simply couldn't fund clinical trials for children.

Similarly, in 2025 we plan to hold our first in-person conference since 2019. This will be a hybrid event to maintain the reach of our virtual symposium while allowing families who can attend to benefit from the unique peer support provided by such a setting.

Ultimately, everything the charity seeks to achieve depends on our fundraising efforts, and on the generosity of those who support us. The landscape remains a challenging one. There is no shortage of worthy charities, including those with links to neuroblastoma. Solving Kids' Cancer UK belongs to the community it serves, and our primary task is to deliver for children and families. But we must also translate that delivery into ongoing and increased support. We're incredibly grateful to everyone who helped us over the last year; our corporate partners, patrons, donors, supporters and all who volunteered their time. Our hope for a better future for every child with neuroblastoma drives us forward. It is only through your support that we can turn that hope into reality.

Nick Bird
Chair of the Board of Trustees

Accelerating research. Driving change. Unlocking hope for children with cancer.

Welcome from our Chief Executive Officer

As we close the chapter on another busy year at Solving Kids' Cancer UK, I am proud to share this year's Annual Report with you and showcase the impact we've made together.

Our research initiatives have seen groundbreaking advancements. We successfully concluded the ACTION grant call, bringing together international partners to award a $2 million grant for an innovative approach to accelerating clinical trials and evaluating novel therapies. We renewed funding for the Senior Neuroblastoma Clinical Trials Coordinator at the Clinical Trials Unit in Birmingham. This role has been pivotal in accelerating neuroblastoma trials availability for children. Extending funding for the MiNivAn clinical trial and supporting the BIOPORTAL project to improve neuroblastoma understanding are significant strides in our quest to find better treatments. These efforts are not just milestones; they represent hope and new possibilities for children who currently have limited treatment options.

Support for families remains at the heart of our mission. This year, we delivered our first post-treatment and bereavement coaching programmes and provided crucial pastoral grants and Care and Connect Bags to families in need. Our Neuroblastoma Parent Global Symposium introduced a new psychosocial programme, offering seminars and peer support that empower families and survivors. The stories shared on our new "Stories of Hope" page are a testament to the strength and resilience of those we support.

Our advocacy efforts have gained momentum with the launch of the Unlocking Hope campaign, which has significantly increased our presence in Westminster and Parliament. We continue to lead in research advocacy, working with clinical trial steering groups and international research networks to push for advancements in paediatric cancer treatment options.

We are proud of the growth in public support and awareness. Our new charity brand film, launched at the iconic Mayfair Hotel, has helped raise awareness and attract new supporters. Events like the British Racing Greats fundraiser and our Christmas Carol Concert brought our community together, showcasing the incredible spirit of our supporters.

Behind these achievements is a robust infrastructure and dedicated governance. We launched a new website, enhanced our Customer Relationship Management (CRM) system, and moved into new office premises, thanks to corporate support.

None of this would be possible without the tireless efforts of our supporters. Whether running, canoeing, head-shaving, or carol singing, every effort makes a profound difference. Special thanks to our Patron, Carl Cavers, and the Sumo Group team for their unwavering support and a huge welcome to new celebrity Patron, Kellie Bright.

As we look to the future, we are inspired by the children and families we serve and motivated by the generosity of our supporters. We remain steadfast in our mission: to see a world where no child dies from neuroblastoma or suffers due to the treatment they receive. With your continued support, we will make this vision a reality.

Thank you for being a part of our journey.

Gail Jackson
Chief Executive Officer

Our impact

£5.2 million
invested in childhood cancer clinical trial development.

Supported more than
1,000 families
affected by neuroblastoma.

Supported over
55 families
to access
life saving treatments
and clinical trials in the UK and abroad.

Facilitated a
landmark collaboration
between the Children's Oncology Group in North America and the SIOPEN research network in Europe.

Formally challenged the decision by the National Institute for Health and Care Excellence not to approve anti-GD2 immunotherapy for children with neuroblastoma in the UK, paving the way for it to become part of frontline treatment.

Funded first ever
dedicated
neuroblastoma
Clinical Trials Coordinator
In the UK.

Hosted the award-winning Neuroblastoma Parent Global Symposium, welcoming more than
1,660 participants
from over
50 countries.

Co-authored
the first paediatric oncology advocate-only manuscript
to be published in the esteemed Journal of Clinical Oncology.

Solving
Kids'
Cancer
UK

Strategic plan 2022-2027

We are fighting for a future where no child dies of the childhood cancer neuroblastoma or suffers due to the treatment they receive

Our strategy

To underpin the delivery of our five-year strategy, our work will be guided by an internal implementation plan centred around three key enablers and a clear focus on our vision and values.

Sustainable
We will ensure our charity remains financially robust to deliver against our strategic objectives, securing the funds required.

Good governance
We will continue to build a strong culture of compliance, transparency and continuous improvement at all levels of the organisation.

Impact
We will measure and showcase the impact of our work and demonstrate return on investment to our supporters.

Our values

Caring

We care passionately about children with neuroblastoma, their families, and all those who care for them, including our staff, volunteers and supporters.

Transparent

We are open and honest about all that we do and how we do it.

Collaborative

Relationships are at the heart of our work – from the children and families we work with, to the individuals, organisations and networks that are involved in their care.

Inclusive

Our services are developed to ensure they meet needs and we aim to make them accessible to all.

Determined

We lead with tenacity and are unfaltering in our drive to help, support and fight for children with cancer.

Hopeful

We have a strong sense of optimism and hope is at the heart of all that we do.

Our three pillars

Our work is driven by three key pillars

Research

Accelerate clinical trial development

We will focus on the development of new treatments by investing in clinical research and working with valued partners for maximum impact.

Prioritise the needs of children

We will engage with families to identify areas of unmet need, challenging experts to find solutions and work together to deliver maximum impact through the research we fund.

Foster collaboration

We will build and strengthen international partnerships to share expertise, best practice and resource, whilst building knowledge.

Support

Reach ALL families

Every family of a child diagnosed with neuroblastoma in the UK will have access to our support service from the point of diagnosis.

Broaden range of support

We will develop and expand our support offer in line with what families tell us they need.

Inform and support decision-making

We will ensure families have access to the most current and scientifically robust data from around the world and support their decision to access the best treatment possible.

Awareness

Research advocacy

We will amplify the voice of the children and parents, seeking to advance science and understanding of the disease alongside patient-centric research.

Patient advocacy

We will champion the needs of individual children and their families, providing parent-led support around decision-making to improve treatment outcomes.

Awareness and campaigning

We will raise the profile and support the treatment needs of children with neuroblastoma and other childhood cancers with the general public, government and public bodies.

Solving Kids' Cancer UK
Research

We drive and invest in pioneering clinical research, focused on finding treatments that are more effective and less toxic.

Our research mission is led by parents of children affected by neuroblastoma alongside our expert Scientific Advisory Board, ensuring we are focusing on unmet needs and investing in the most cutting-edge research to increase the UK's clinical trial footprint, allowing more children to access innovative therapies closer to home. This is an urgent and vital need, as neuroblastoma remains one of the leading causes of death from cancer in children.

2023/24 summary

Funding Boost to Help Clinical Trial Delivery

In January 2024, we renewed funding for the Senior Neuroblastoma Clinical Trials Coordinator at the Cancer Research Clinical Trials Unit in Birmingham. Initially funded in 2018, this role has been pivotal in accelerating neuroblastoma trials availability for children, enabling new trials to begin setup even before funding is secured, by supporting with grant applications and development of documentation for regulatory submission and trial setup. The partnership has enhanced our understanding of the trial landscape, informing our new External Affairs Strategy to expedite clinical trials for childhood cancer in the UK. Extending the funding for a further three years ensures the continuation of vital work to advance neuroblastoma trials, critical to improving treatments for children.

Extending Hope for Families

The MiNivAn trial, funded by Solving Kids' Cancer UK and partner organisations since 2018, is an international study testing a combination of immunotherapy and specialised radiotherapy for high-risk neuroblastoma that has recurred or resisted standard treatments. Led by Dr Juliet Gray at University Hospital Southampton, the trial met its recruitment target by the end of 2023, benefiting numerous children in the UK. Early analysis shows some encouraging responses, although further data is needed to fully assess treatment effectiveness. Given the limited options for relapsed and refractory high-risk neuroblastoma, the MiNivAn trial offers families a crucial opportunity to access innovative therapies for their children. In recognition of its importance, Solving Kids' Cancer UK and partner organisations have committed an additional £295,207 to extend the trial, to enable a better understanding of treatment effectiveness and how best to develop it further. To ensure the continuation of these promising findings, we have funded a further trial investigating specialised radiotherapy, led by Drs Sally George and Daniel Morgenstern, which aims to open in the UK and Canada in 2025.

Ambitious New Plan for Transatlantic Clinical Trials

The ACTION Consortium, a collective force of five non-profits brought together by Solving Kids' Cancer UK (SKC) and dedicated to Advancing Clinical Trial Implementation and Optimisation in Neuroblastoma, has concluded its first grant call. A high-caliber proposal has been selected to receive $2 million for an innovative approach to accelerating clinical trials and evaluating novel therapies. The winning application unites a distinguished team of neuroblastoma clinicians and translational researchers to address the urgent need for a multinational, intercontinental network for early-phase clinical trials, integrating biological data with clinical outcomes. This collaboration paves the way for addressing rare patient groups defined by biological features in future studies. The potential impact on the field, and most importantly, for children with neuroblastoma, could be profound.

Kayla was diagnosed with high-risk neuroblastoma in May 2021, when she was three years old. This began when Kayla experienced ongoing pain in her legs, which led the family to A&E where multiple investigative scans confirmed their worst fears, Kayla had cancer.

In the months after her diagnosis, Kayla bravely took on the grueling treatment, involving chemotherapy, surgery, stem cell transplant, radiotherapy and immunotherapy. Despite this, her family was devastated when scans in November 2022 showed the cancer had progressed. With limited options available at this stage, Kayla was put on a new treatment plan to manage her disease as best as possible.

At the start of 2024, thanks to the funding extension for the MiNivAn trial at University Hospital Southampton, Kayla was able to access a novel combination of therapies to try and treat her disease. The MiNivAn study is an innovative trial that is investigating a new combination of immunotherapy and specialised radiotherapy. Kayla is one of the children who will benefit from the trial extension, giving her and her family the all-important hope that they need.

"Trials are so important for these children. There really aren't enough trials out there unfortunately, so options can become very limited. We are so very lucky that this is available." - Stacey, Kayla's mum.

Advocacy in Action at the Advances in Neuroblastoma Research Congress

In May 2023, we were proud to be a Gold Sponsor of the Advances in Neuroblastoma Research (ANR) conference in Amsterdam, in partnership with our friends at Solving Kids' Cancer US. This biennial event was an opportunity for the global neuroblastoma research community to come together, share knowledge, exchange ideas, establish new partnerships and generate new hypotheses.

For the first time in the history of the conference, advocates were invited to be part of the main agenda, a recognition of the important perspective they bring to the table and tenacious work done to build relationships with the scientific and medical community. We were proud to see our Chair of Board of Trustees, Nick Bird, share his views on the role of advocates in improving the survival of children with neuroblastoma.

We also hosted a patient advocate-led symposium to stimulate discussions on moving the field forward to improve outcomes for all children with high-risk neuroblastoma. This included articulating a vision for neuroblastoma therapy extending beyond what is right around the corner and considering the paradigm shifts that are needed to turn a broad vision into reality. A manuscript is in preparation summarising the themes of the discussion.

2024/25 goals

- Support the launch of new clinical trials TACTIC and MINT to improve access to novel therapies for children with neuroblastoma.
- Refine our research strategy based on experience to date and ensuring optimal value for money.
- Host a scientific meeting alongside an in-person/hybrid parent conference to further strategic research goals.
- Deliver patient-partner commitments in European grants, amplifying the voice of children (ALADDIN, MONALISA).
- Build on existing collaborative partnerships to fund and advance research benefiting children with neuroblastoma.

Solving Kids' Cancer UK
Support

A diagnosis of neuroblastoma can be overwhelming and life-changing for the entire family. Our unique Family Support Service is dedicated to the neuroblastoma patient and parent community in the UK. The team blends personal experience and acquired knowledge, as parents of children affected by neuroblastoma, with professional skills and experience.

We carefully tailor the support given based on the bespoke needs of the family to help ease practical, financial and emotional burdens and pressures that a neuroblastoma diagnosis brings. We also help to expertly guide families through often difficult, complex and fraught decision-making processes.

Our service is built upon hope and places children at the heart of all we do. It focusses on the here and now, easing the immediate burdens and pressures that a neuroblastoma diagnosis brings.

2023/24 summary

Coaching programme
This year we undertook the pilot Post Treatment and Bereavement Coaching Programmes with Life After Cancer and all those that took part said it had a positive impact on their wellbeing.

Solving Kids' Cancer provides support once you have finished treatment that is 100% tailored to your experience as a neuroblastoma parent. Doing their workshop meant I could meet other parents and explore my own identify after being a mum of a child who had cancer for 2 years. We spoke about things like fear of relapse and finding purpose and it made me feel much less alone. It's amazing that SKC continue to support parents and recognise that ending treatment is a really difficult time and not the "relief" that many think it is." Parent attendee.

Now, with in-house trained coaches we are preparing to launch our SKC coaching programme. The aim is to ensure that as many parents as possible have access, if they wish, to this support – either in post treatment or bereavement.

Care and Connect Bags
This year, the Care and Connect Family Support Bags have directly supported 49 families and their children in their time of need. For some, this is their first point of contact with our charity.

"The Care and Connect bag was such a lovely gesture and really made us smile during a difficult time. It made us feel like people were looking out for us and supporting us. The items in the bag were really practical and useful but also really great quality so it felt like a special treat to use them. We were so grateful for the bag, as a family it really perked us up to receive the bag and see all the goodies inside." Neuroblastoma family.

Big Love Fund
During 2023/24, we have awarded 47 grants through the Big Love Fund – this includes families in bereavement.

Neuroblastoma Parent Global Symposium
We were so proud to deliver a new psycho-social programme of seminars and interactive sessions at our Neuroblastoma Parents Global Symposium. Themes around supportive care were discussed, with an emphasis on mental and physical wellbeing of families and children affected by cancer. Clinical experts shared information and offered intervention strategies.

"The peer support session was great. I also liked how there were parallel sessions running, and we had an opportunity to send questions during the session which were then addressed at the end."

Stories of Hope
We listen to our parent community. We know the value of hope to families facing their toughest challenge and helping to provide hope to families is a central part of Solving Kids' Cancer UK's mission. In 2023, we introduced a new area on our website called Stories of Hope.

Among the incredibly sad stories, there are also stories of hope, which we are pleased to be able to share and celebrate with you. The stories featured, shared with permission, are of children and young people who have been diagnosed with neuroblastoma, have completed treatment and are now in remission and doing the things they enjoy most in life.

"I find social media a bit hard sometimes with all the bad news, so just wanted to say I love the stories of hope on your website."

2024/25 goals

- Deliver a hybrid conference to enable neuroblastoma families the option to come together in-person for peer support, hear about the latest developments in neuroblastoma research and take part in psycho-social workshops, whilst also providing access to the conference remotely to ensure we are able to reach all families.
- Officially launch SKC's bespoke coaching programme for neuroblastoma parents.
- As Advocates, ensure continuous engagement with new trials and developments within the research landscape such as DFMO and CAR-T.
- Present unbiased information to support parental decision-making by working closely with Clinicians and maintaining and building strong networks in the global research landscape.

Alice was diagnosed with high-risk neuroblastoma in April 2022, when she was eight years old.

For 14 months, Alice endured grueling treatment for neuroblastoma including taking part in two clinical trials at the Sant Joan de Déu Barcelona Hospital. When end of treatment scans confirmed Alice was clear of disease in June 2023, the family flew out to New York in July for Alice to start the bivalent vaccine clinical trial with the aim of keeping her cancer away.

Alice is now a ten-year-old bubbly, bright, beautiful, and brave young lady. She loves to spend her time singing, running and keeping family and friends entertained. Alice says, "I'm back in normal life and I love it!"

Alice's mum and dad, Dylan and Norah, were supported by Solving Kids' Cancer UK to navigate the treatment landscape and make crucial decisions at an already difficult time.

"We found out about Solving Kids' Cancer UK through our early research into neuroblastoma. They had lots of very useful information available, such as the recordings of the Neuroblastoma Parent Global Symposium. Initially, the most beneficial support we received from SKC UK was sharing impartial and easy-to-understand information about pathways available in Europe for neuroblastoma patients. They were helpful in sharing advice and information on different treatment types and the associated trials that were being conducted. This helped our family with some very difficult decision-making and provided comfort and hope that we were not alone in facing the challenges of neuroblastoma." Dylan, dad to Alice.

Solving Kids' Cancer UK
Awareness

In order to drive long-term change and improvement to the lives of children with cancer, we are committed to raising the profile of childhood cancer, and tackling systemic challenges that stand in the way of progress. Through strategic partnerships across the sector, we are amplifying the voices of children and families, driving action amongst experts, and influencing key decision-makers to facilitate national change.

Unlocking Hope
To mark the end of Childhood Cancer Awareness month, last October we launched the Unlocking Hope campaign, publishing our first-ever public affairs strategy. In our strategy, we set out a mission to accelerate clinical research into children's cancers in the UK. Currently, there are numerous barriers and bottlenecks in the UK healthcare system that are hindering the progress of clinical trials, and ultimately limiting the progress we can make for children with cancer. By developing this new strategy and creating the new role of Public Affairs & Advocacy Lead, we have paved strong foundations for our campaigning and influencing work, to drive real change and bring real impact for children and families.

Building our relationships with parliament
With a strategy established to steer our campaigning efforts, we began our parliamentary engagement activities to establish new relationships that will help to champion our cause in Westminster and beyond. In August 2023, we were pleased to support a debate on Neuroblastoma Treatment, called by former MP, Peter Gibson, thanks to our friends at the Luke Bell Foundation. The debate involved constructive conversation about ways to tackle the harsh reality faced by children diagnosed with neuroblastoma, and recognition of SKC UK's efforts to drive this issue forward. In December 2023, we secured several MP meetings to raise awareness of our mission, bringing new connections in parliament and better awareness of SKC UK amongst key influential figures.

The vehicle to drive change
In addition to garnering political support for our mission to accelerate clinical research for children's cancers, we have put a focused effort on what we can achieve in collaboration with the research and healthcare communities to facilitate change. As a research funder and patient organisation, SKC UK has developed strong relationships with stakeholders across the whole childhood cancer sector. To bring about impactful change for children with cancer, we are using our position to convene a new multistakeholder initiative with a focus on accelerating clinical research in the UK. The initiative will be fast-paced and solution-driven, with the intention to develop actionable steps that can be implemented in collaboration with key decision-makers in government. In early 2024, we recruited Pam Kearns, Professor of Clinical Paediatric Oncology, as an independent Chair for the initiative, and aim to formally establish the group by the start of 2025.

Putting children at the heart of research
Alongside our strategic efforts to reshape the landscape for future trials, we continue our commitment to engaging in current research, to ensure that the needs of children and families are put at the front and centre of progress. This year, our research team has participated in several Trial Steering Committees, bringing patient perspective into conversations that shape trial setup and delivery.

In April 2021, just after her sixth birthday, Eden was diagnosed with high-risk neuroblastoma after weeks of suffering with leg pain and fevers. X-rays, MRIs, and CT scans confirmed the awful news that Eden had cancer, and within hours she began treatment, which started with chemotherapy.

Being diagnosed at the height of the COVID-19 pandemic caused complications and delays, but thankfully Eden completed frontline therapy, with her end of treatment scans showing she was in remission in November 2022. Following this, in December 2022, Eden enrolled on a clinical trial for an experimental relapse-prevention therapy in New York, which she will continue on until late 2024.

In July 2023, Eden's family featured in our campaign with the Daily Express - Back Britain to Beat Childhood Cancer - proudly holding up a letter to the former Health Secretary, Steve Barclay, signed by 15 families, urging for change. Eden's family bravely shared their experience of travelling abroad to access the Bivalent Vaccine trial in New York to demonstrate the need to make more clinical research available for families here in the UK.

Since then, Eden's parents, Jen and Lee, have shown continuous support for Solving Kids' Cancer UK's campaigning efforts, including our Unlocking Hope campaign, helping us to pave the way for change.

We have also strengthened the position of advocates in numerous international research networks, including the European Neuroblastoma Research Network (SIOPEN), where our Head of Research Leona Knox participated in the Annual Meeting in Ljubljana, focusing on expanding the SIOPEN advocate network across all European countries.

Paving the way for future advocates
Research advocacy is a nuanced field, but one that brings important benefit to the patient community. An important element is ensuring that advocate involvement is sustained long into the future, so that the progress made so far can continue for future generations of children. SKC UK is committed to expanding our work to support this, and at this year's Neuroblastoma Parent Global Symposium, we held a dedicated session on Research Advocacy. This was aimed as an introduction for parents interested in becoming involved in advocacy activities, and we look forward to building on this in the coming year, to strengthen the support available for future advocates.

2024/25 Goals

- Launch Solving Kids' Cancer UK's manifesto for children's cancer research.
- Host our first parliamentary reception.
- Attend first major political Party Conferences and develop a strong parliamentary network in the new government.
- Convene and coordinate a UK multistakeholder initiative to drive forward our aim to accelerate clinical research into children's cancers.
- Develop a pilot advocate mentoring scheme for parents and young people.

PARENTS' DESPERATE PLEA TO BARCLAY

Behind every face is a story telling why UK must fund trials of child cancer jab

DAILY EXPRESS CRUSADE
BACK BRITAIN TO BEAT CHILDHOOD CANCER

'We have got to give her every chance we can'

COMMENT
GAIL JACKSON

NEXT SALE
AT LEAST 50% OFF ALL NEXT SALE ITEMS
SALE STARTS ONLINE & IN STORE TODAY AT 6AM

Your Support

Over the last year, we have been humbled by the support we have received from our community and event fundraisers and the ongoing support we have received from our corporate supporters. Highlights from the year include:

British Racing Greats

In May 2023, Solving Kids' Cancer UK alongside SpecialEffect had the honour of being charity beneficiaries of a first-of-its-kind unique charity track event celebrating the greatest racing games ever made. Held at Donington Park Circuit, the amazing day was brought together by the generosity of so many individuals and companies and hosted by Ben Collins (The original, The Stig) with special guest, Jodie Kidd. An incredible £100,000 was raised and split between the two charities.

The Irish Solicitors Bar Association, London – Autumn Ball

Our friends at The Irish Solicitors Bar Association, London held their Autumn Ball at Claridge's in aid of Solving Kids' Cancer UK. Our Head of Research, Leona Knox, spoke at the event sharing her personal story of her son's passing from neuroblastoma at the age of five and the urgent need for more childhood cancer research and support. The ball raised over £24,000 for Solving Kids' Cancer UK.

Sumo Group

We are proud to continue our ongoing charity partnership with Sumo Group, a collaboration that has significantly advanced our mission. Through a variety of joint initiatives and fundraising efforts, Sumo Group has demonstrated an unwavering commitment to supporting our cause. Their continued generous contributions to our Care & Connect Support Bags, their support with making our first charity film and introductions to their networks have been invaluable. Together, we are making strides towards a better future for children with childhood cancer.

Swimming Challenge

For Childhood Cancer Awareness Month in September 2023, Jonathan took on a 40km (1600 lengths) swimming challenge in memory of his daughter Bella, who he tragically lost to high-risk neuroblastoma on her sixth birthday. He raised an incredible £21,844 for children with neuroblastoma and to support more research

Fundraising walk in memory of friend

Eleven-year-olds Jessie, Gabriella and Phoebe wanted to raise money in memory of their best friend, Kitty, who devastatingly passed away in 2022 after being diagnosed with neuroblastoma. The girls organised and walked more than 25 miles in one day.

At times the terrain was very hilly, and the weather was treacherous, but they never complained once! The girls raised over £4,000 for SSolving Kids' Cancer UK. Jessie, Gabriella and Phoebe were awarded hero awards at our annual Carol Concert for their amazing fundraising for their friend'.

Family Fun Day

On 8th July 2023, we hosted our annual Family Fun Day at the picturesque Knebworth House, bringing together over 40 families for a delightful and child-friendly event. The day was filled with a variety of activities catering to all ages and interests, helping families to foster new connections and ensuring everyone had a wonderful time.

Families enjoyed various activities, from ball pits, face painting to arts and crafts. We Can Kick It led football games outside, while an indoor gaming room provided additional entertainment. Guests were treated to a delicious BBQ lunch and refreshing treats from an ice-cream van, rounding off a truly memorable day for all.

Thank you to Flix Interactive for supporting this event.



Events

Neuroblastoma Parent Global Symposium 2023

On 3rd November 2023, we held our fourth Neuroblastoma Parent Global Symposium (NPGS) in partnership with Solving Kids' Cancer US. The award-winning global event aims to inform and empower families affected by neuroblastoma, connecting them with those who work to treat, help and support them. The event welcomed over 360 participants who heard from world-leading scientific and clinical experts working to push boundaries in the treatment of neuroblastoma, as they provided updates on the latest cutting-edge research. It also included Q&A sessions with experts and virtual conversation rooms on specific topics where families could come together for peer support.

We are grateful for the support from Recordati Rare Diseases, Y-mAbs Therapeutics Inc, United Therapeutics Oncology, Sanofi, US WorldMeds and GRC World Forums in making this event possible.

Film Premiere

Thanks to our incredible corporate partner, Sumo Group, SKC UK were proud to officially launch our new charity film to showcase our work and impact. The film premiere was held at the iconic Mayfair Hotel in London with guests including existing and new supporters of the charity, clinicians and researchers and most importantly, many of the families who appeared in the film. Our guest speakers included our Head of Family Support, Vicky Inglis; Head of Research, Leona Knox; and Trustee, Alex Lane, all of whom shared their candid personal experiences to a very moved audience.

Christmas Carol Concert

On 5 December 2023, we packed out Holy Trinity Church, Sloane Square, London for our sold-out Christmas Carol Concert and raised over £25,000 for children and families affected by neuroblastoma.

We had a range of performers including the renowned London Show Choir and the cast and crew of EastEnders. We also presented our special Hero Awards to those in the community who made a real difference in 2023.

One of the highlights was undoubtedly a performance from the incredible Louis Moorhouse and fellow blind musician, Sirine Jahangir. Louis was diagnosed with stage 4 neuroblastoma when he was 18 months old. He had a primary tumour on his adrenal gland and another tumour in his nasal cavity.

The tumour in his nasal cavity crushed his optic nerve leaving him permanently blind and the toxic side effects of treatment also left Louis partially deaf too. Despite having difficulties as a result of neuroblastoma, this incredible young man has not let this hold him back.

After getting his first keyboard, aged eight, he has recently finished university with a degree in music production and is enjoying his work as a mixing engineer.

It was an absolute privilege to have Louis perform at the concert, and we're so grateful to him and Sirine for being a part of it.

Thank you to Miniclip, Laser Quest, PitStop Productions and Anglo Stainless for supporting this event.

Achievements & performance

The second year of our 2022-2027 strategy has been even busier and we have achieved so much across all three of our pillars - Research, Support and Awareness. Alongside this we have maintained a lean and highly effective infrastructure to ensure our teams can focus on driving our strategy.

Solving Kids' Cancer UK

Research

- Successful conclusion of ACTION grant call, brand new clinical trial (TACTIC) and international data platform (MIGHTY) funded.
- Extended funding for MiNivAn clinical trial maintaining this treatment option for children in the UK, and a new molecular radiotherapy trial to open afterwards (MINT) for children who currently have no well-defined therapeutic options.
- Extended funding for the Senior Trials Coordinator in Birmingham and gaining on-the-ground insight to inform our new multistakeholder Partnership approach to accelerating Children's Cancer Trials (IMPACCT).
- Co-funded BIOPORTAL to ensure UK inclusion in pan-European virtual biobank to improve understanding of neuroblastoma.
- Supported, attended and contributed to major international meetings (Advances in Neuroblastoma Research Congress, Amsterdam; Neuroblastoma Drug Development Strategy, Boston)

Support

- Delivered our first post treatment and bereavement coaching programmes.
- Provided 47 Big Love Fund pastoral grants and 49 Care and Connect Bags.
- Delivered a new psychosocial programme of seminars and interactive peer support sessions at our Neuroblastoma Parent Global Symposium, whilst facilitating and moderating key sessions.
- Actively engaged with clinicians and researchers through attendance at SIOPE, REDMAPP and PanCare.

Awareness

- Launched our first-ever public affairs strategy through the Unlocking Hope campaign.
- Increased our presence in Westminster/ parliament through policy engagement efforts (MP meetings, debates etc.)
- Led on the development of UK multistakeholder initiative to accelerate clinical research for children's cancers.
- Continued research advocacy through involvement in clinical trial steering groups and international research networks.
- Increased effort to educate and support future advocates.

Inspire public support for the Charity

- Raised £1,003k of unrestricted income, 32% growth on prior year.
- Launched our new charity brand film at the iconic Mayfair Hotel, welcoming existing supporters, clinicians and families and welcoming new supporters. The event and film will help us to raise greater awareness of the needs of children and their families facing a neuroblastoma diagnosis and broaden our reach to attract new supporters to our cause.
- Launched our new Solving Kids' Cancer UK brand.
- Alongside our partner charity SpecialEffect, delivered the British Racing Greats fundraising event hosted by Jodie Kidd and the Stig, raising over £50k for each charity.
- Welcomed many of our supporters and families to our in-person Christmas Carol Concert with very special performances from the amazing Louis Moorhouse and Sirine Jahangir, the Eastenders Choir and the London Show Choir.
- Secured GamesAid funding for an eighth year running.

Strong governance and infrastructure

- Launched our new website including our 'Stories of Hope' section, providing all our stakeholders with a more user-friendly digital way into the organisation.
- Further developed and embedded our Customer Relationship Management (CRM) system to ensure we can support all our families, research initiatives and donors in the best way for them.
- Following Board review, began our open recruitment process for new Trustees to join our hugely committed and expert Board.
- Thanks to corporate support we have been able to move into new office premises to provide a hub for the organisation's activities and reduce costs.

Future plans

The 2022 – 2027 organisational strategy is hugely ambitious, and we have made a very strong start over the last two years. This year, we will continue to build on these efforts, growing our networks, relationships and activity to deliver a huge programme of very exciting work over the next year across all pillars, and most notably drive a real step change in our advocacy work.

Over the next year we will:

- Continue to effectively and passionately advocate for children and families affected by neuroblastoma and work in partnership with the global neuroblastoma clinical and research communities, to help facilitate more effective and less toxic treatment options for children in the UK.
- Deliver our first-ever Hybrid Neuroblastoma Parent Conference, bringing together the research and clinical community to host scientific meetings and families to come together for peer support, hear about the latest developments in neuroblastoma research and take part in psychosocial workshops.
- Launch Solving Kids' Cancer UK's manifesto for children's cancer research to include the hosting of our first ever parliamentary reception bringing together MP's, families, the clinician and research community and supporters.
- Convene and coordinate a UK multistakeholder initiative to drive forward our aim to accelerate clinical research into children's cancers.
- Formally launch the Solving Kids' Cancer UK coaching programmes, which will be a series of online group sessions for parents of children diagnosed with neuroblastoma following the end of treatment, as well as for those in bereavement, focusing on parental wellbeing and life after cancer.
- Work with our Scientific Advisory Board to refine our existing Research Strategy to enable us to drive progress for children with neuroblastoma as effectively as possible through new research funding opportunities, advocacy efforts and our existing and new research investments.
- Recruit at least two additional Trustee Board members based on analysis of skills and experiences needed in accordance with the charity's five-year strategy.
- Continue to grow and strengthen our fundraising pipeline through expansion of our corporate partnerships, development of an individual giving programme and further development of our Named Funds so that families have a supported way to raise funds in the name of their child that support the core activities of the charity.

Structure, governance & management

Governing document

The Trustees, who are also Directors for the purposes of company law, present their report and the financial statements of the company for the year ended 31 March 2024.

The charity is controlled by its governing document, the Articles of Association, and constitutes an incorporated registered charity. The charity was incorporated on 30 March 2010 at Companies House, was entered in the Register of Charities on 20 April 2010 and is administered by the Trustees. At their discretion, the Trustees may spend all or part of the capital of the charity in furthering its Objects, in the following ways:

i. To raise funds. The Trustees must not undertake any substantial permanent trading activity and must comply with any relevant statutory regulations.
ii. To buy, take on lease or in exchange, hire or otherwise acquire property and to maintain and equip it for use.
iii. To sell, lease or otherwise dispose of all or any part of property belonging to the charity.
iv. To borrow money and to charge the whole or any part of the property belonging to the charity as security for repayment of the money borrowed.

Aims and objects

The charity's objects ("Objects") are specifically restricted to the following:

- To advance the understanding and treatment of cancer in children through the greater awareness, provision of equipment, access to treatment protocols in hospitals and medical centres and clinical research aimed at improved diagnosis and treatment anywhere in the world.
- To advance the education, relieve the sickness and the poverty of persons living anywhere in the world through the provision of equipment, financial assistance and by any other charitable means that the Trustees in their absolute discretion think fit.

Public benefit

The Trustees give due regard to the public benefit provided by the charity in relation to its charitable purpose as set out by the Objects and due consideration to the relevant guidance issued by the Charity Commission. The Trustees will continue to ensure that the principal activities of the charity are to provide public benefit.

Board of Trustees

Solving Kids' Cancer UK is governed by the Board of Trustees, chaired by Nick Bird. The Trustees determine the charity's strategic direction and oversee progress against objectives. It is responsible for governance and for upholding the charity's values. The charity must have at least three Trustees. The day-to-day running of the charity is the responsibility of the Chief Executive Officer.

The Board of Trustees supports the principles of good governance set out in the new Charity Governance Code (see www.charitygovernancecode.org) and also the continuous improvement model which the Code promotes.

The Board of Trustees receives periodic technical briefings on neuroblastoma research, have joint sessions with the Chair of the Scientific Advisory Board and attend the annual Neuroblastoma Parent Global Symposium and other relevant conferences/ meetings.

The Board of Trustees has formal board meetings six times during the year. In accordance with the charity's Articles of Association, Trustees must undertake to attend meetings regularly and any Trustee failing to do so may be duly removed from their position.

The quorum necessary for the transaction of Trustee business at an ordinary meeting is three Trustees or two thirds of all Trustees, whichever is greater. The Trustees agree that the nominated Chair has the casting vote for decisions where there is equal weighting.

The Board selects new Trustees based upon their empathy with the Objects of the charity, skills and experience to help provide the appropriate level of governance and oversight for the charity to be effective, coupled with their ability to commit the necessary time for Board meetings and other key events.

Structure, governance & management Continued

During the year, the Board has reviewed their composition and made the decision to recruit a number of additional Trustees, which is underway. They also updated their Memorandum and Articles to reflect current practice. With the support of the Scientific Advisory Board, the Trustees committed five new research grants in partnership with others.

Trustee induction procedures include completing relevant training and working with staff and existing Trustees to understand the organisation and develop internal relationships, to include one-to-one meetings with the CEO, Chair of the Board, Trustees and members of the Leadership Team. The induction also covers governance processes, strategic planning and finance, so that new Trustees are equipped with relevant knowledge about the organisation and its priorities. New Trustees are provided with a Role Description and Person Specification and Board Code of Conduct.

Scientific Advisory Board

Solving Kids' Cancer UK's Scientific Advisory Board (SAB) is an independent body of experts who are responsible for providing expert guidance and support to help us achieve our research goals, as well as overseeing our robust, Association of Medical Research Charities accredited grant award process. Their advice and recommendations are presented to the Board of Trustees via our research team.

The SAB's insight and expertise has been invaluable again this year running an extremely rigorous grant award process for our ACTION consortium grant call, providing $2 million of partnership funding to a new plan for Transatlantic Clinical Trials. Overall, we made five separate significant grant awards within the year under the SAB expert guidance and have strongly managed and influenced the research programmes within our portfolio through regular monitoring by the SAB.

The Trustees would like to extend their wholehearted gratitude to every member of our Scientific Advisory Board, for their continued dedication to push the charity's research goals forward, for the benefit of children with neuroblastoma in the UK, and internationally. A special thanks goes to the Chair of our Scientific Advisory Board, Professor Andy Pearson, for providing his expertise and continued tireless commitment to help children with neuroblastoma, and for his incredible enthusiasm and support for the work of Solving Kids' Cancer UK.

Staff remuneration

All salaries, including that of the Chief Executive Officer, are based upon an assessment of the employment market, the skill levels required, the size and financial performance of the charity and the salary levels required to obtain the services of the best staff.

Equity, diversity and inclusion

Solving Kids' Cancer UK has a strong, caring ethos and is firmly committed to equity, diversity, and inclusion (EDI), which is integral to our five-year strategy and values.

We are committed to embedding principles of equity, diversity, and inclusion, ensuring that our operations, activities, and services are designed and open for everyone to be included, and to fostering culture, behaviours, and practices in support of social justice.

EDI is fundamental to achieving our charity objectives to reach and be there for all families affected by neuroblastoma, and for the health and wellbeing of all those we work with and exist for. We want everyone to feel included and believe in the importance of reflecting different perspectives, experiences, and skills, including from those with lived experience of neuroblastoma, within our staff, board, and volunteer teams.

We are not EDI experts, we do not have all the answers, and we will not always get it right - but this can't and won't hold us back. We are committed to learning, to listening and to creating safe spaces for difficult conversations that will inspire and lead to positive and lasting change.

Safeguarding

Our work and practice is underpinned by safeguarding principles with the aim of protecting children and young people and enhancing their welfare. Solving Kids' Cancer UK always works in accordance with legislation, statutory guidance, and best safeguarding practices. Solving Kids' Cancer UK has robust safeguarding policies and procedures in place and all staff and Trustees receive dedicated safeguarding training upon induction with regular updates as required.

All hiring managers are required to access Safer Recruitment training to ensure that our recruitment processes are robust, with an emphasis on ensuring the safety and welfare of the children and families we support. All staff and Trustees are required to have a basic DBS check and clearance before commencing their role with Solving Kids' Cancer UK, and this is extended to any volunteer or service provider that may have regular direct interaction with the children and families we support.

The charity reviews and revises safeguarding policies and procedures at regular intervals, at least annually, and has a designated safeguarding lead within the leadership team and a Trustee with designated safeguarding oversight.

Volunteers

The Trustees are extremely grateful for the considerable contribution made by the charity's volunteers and fundraisers in support of children with neuroblastoma, including our Patrons, our Parent Involvement Forum members and all those who lend their time, expertise and resources in furtherance of our charitable objectives.

We couldn't do all we do without wonderful volunteers. From the amazing Louis Moorhouse and Sirine Jahangir performing at our Christmas Carol Concert alongside the brilliant Eastenders choir and the London Show Choir, the amazing volunteers who help run our Family Fun Day and the parents who formed a focus group to develop our coaching programme or facilitated peer support sessions at our Neuroblastoma Parents Global Symposium, and to everyone else who has helped us this year. We are all part of team SKC and we thank every one of you from the bottom of our hearts.

During the year, volunteers supporting the charity collectively contributed over 3,200 hours and we are hugely grateful to them all.

Our legal & administrative details

Registered charity name
Solving Kids' Cancer UK (changed from Solving Kids' Cancer Ltd on 25 August 2023)

Charity registration number
1135601 (England and Wales)
SC045094 (Scotland)

Company registration number
07208648

Registered office (from 1st Sept 2023)
Unit 02-03 Salisbury House,
29 Finsbury Circus
London EC2M 7AQ

(Previous address) Coram Campus
41 Brunswick Square
London WC1N 1AZ

Trustees
The Trustees who served the company during the period were as follows:

Nick Bird (Chair of the Board of Trustees)
Joseph Tabone (Board Policy and Safeguarding Lead)
Matthew White (Equality, Diversity and Inclusion Lead)
David Coulon (Treasurer)
Alexandra Lane
Dr Áine McCarthy
Carl Cavers (from 16th Sept 2024)
Stewart Leaver (from 16th Sept 2024)
Ioannis Topsakalidis (from 16th Sept 2024)

Company Secretary
Gemma Wadsley

Chief Executive Officer
Gail Jackson

Leadership Team
Claire Hislop (Head of Operations)
Danielle Russell (Head of Fundraising and Engagement)
Gemma Wadsley (Director of Strategic Finance)
Leona Knox (Head of Research)
Vicky Inglis (Head of Family Support Service)

Patrons
Carl Cavers
Kellie Bright
Rob Brydon

Auditor's
Shipleys LLP
Chartered Accountants & Statutory Auditor
10 Orange Street, Haymarket
London WC2H 7DQ

Bankers
National Westminster Bank
Church Road Branch
London NW4 4DS

Investment managers
CCLA Investment Management Limited
1 Angel Lane
London EC4R 3AB

Solicitors
Withers
20 Old Bailey
London EC4M 7AN

Our finances

Overview

2023/24 was a very impactful year for us with five large research grants awarded and positive growth to our undesignated income and networks, which has further embedded strength into our income streams for the future. We saw lower designated income as fewer families raised funds for treatment, which potentially reflects the current options available in the UK. Our finances remain tightly controlled with lean expenditure across the organisation.

We had planned for an undesignated deficit for the year to manage our reserves position and enable investment in year two of our strategy ahead of wider income growth, and the undesignated deficit of £111,322 is very much in line with these plans.

Overall, we are presenting a deficit of £424,084, which largely relates to the £1,262,051 of Research commitments in year using previously raised funds.

Income

Our total income for the year was £2,476,390 (2023: £2,991,524). This comprises £1,003,793 undesignated funds (2023: £760,051); £1,285,522 designated funds (2023: £1,614,036) and £187,075 restricted funds (2023: £617,437).

Our undesignated income is made up of voluntary and investment income, which supports all our charity's internal activities. This includes our family support provision – offering pastoral care and grants to support families and providing evidence-based, impartial information to support parents in their choice of treatment options for their child, and to access treatments and clinical trials if they are not available in the UK. It also includes our internal research team and infrastructure, all our fundraising activities and our operational running and governance costs. Our designated income of £1,285,522 relates predominantly to funds designated in the name of a child to support treatment options with a full breakdown of our designated and restricted fund income in notes 20 and 21.

Overall income has reduced by £515,134 with this being split across designated family funds and restricted research income offset by undesignated funds which have increased for the year.

Expenditure

Expenditure increased significantly for the year to £3,226,862 (2023: £1,884,851). The growth largely relates to charitable spend which was up £1,320,939 to £2,884,684. The biggest element of this increase is the Research Grants spend totaling £1,262,051 which includes the five large Research grants. Children's treatment costs were just slightly down at £639,537 (2023: £685,390) whilst Family Support spend, which includes grants to families was up at £176,402 (2023 122,200). Fundraising costs were flat at £342,178 (2023: £321,106).

Within these costs, we keep our support spend as lean as possible and this remains flat on the prior year at £406,009 (2023: £395,141).

Investments

Given the nature of the organisation, supporting very young children and their families, our investment objectives are primarily to invest in an ethically sound manner to protect the value of the charity's assets against inflation, and provide modest returns through a combination of income distribution and capital growth. In addition to being mindful of the nature of investments made on behalf of the charity, the Trustees' appetite for risk is also influenced by the significant amount of funds that are designated for future purposes. The COIF Charities Ethical Investment Fund aims to provide a long-term gross return of 5% per annum net of inflation. Within this, the fund aims to deliver a consistent annual distribution of income and operate with a level of volatility (risk) that is no greater than 75% of the volatility of the UK equity market. The actual return performance (not inflation adjusted) for the year was +13.11% given market strength over the past year, with a three-year figure of +7.34% and the last five years at +8.95%, which is consistent with our aims.

Following a stronger investment year, we are reporting an investment gain of £345,776 (2023: £184,680 loss). Since purchase, the investment has given capital growth of £1,365,164.

Our finances

Continued

Reserves policy

The Trustees have adopted a reserves policy which they consider appropriate to ensure the continued ability of the charity to meet its objectives.

General funds are set aside to meet future costs to support our families and deliver our strategy. At the financial year-end, general funds were £848,659 (2023: £959,981).

General free reserves (undesignated funds excluding fixed assets) were £841,937 and represent 8.9 months' undesignated expenditure (based on the 2025 budget).

Free reserves are calculated as follows:

	2024
	£
Total funds of the charity	12,909,236
Less: Restricted funds	(2,064,050)
Less: Designated funds	(9,996,527)
Less: Fixed assets held for charity use	(6,722)
	£841,937

The reserves policy states that six to nine months of essential running costs should be covered to meet its obligations in the short-term (£567,500-£851,250) based upon the 2025 budget. This is based on an assessment of the organisational risk approach and funding model. This year, we are at the top end of the range as per our plan.

As part of our five-year strategy, we agreed investment in service delivery and income generation ahead of income growth, with planned deficits across the first half of the strategy and this year's deficit in year two of our strategy is in line with this plan. We have another smaller deficit forecast for the 2025 budget, which will result in reserves within our agreed range and still towards the higher end of the range.

This robust financial plan, alongside the need for caution given the continued challenging nature of the external environment for all charities, means that the Trustees are comfortable with the current reserves level and longer-term policy.

Designated Funds are predominantly set aside for the treatment of children or our Research or Investment reserves funds and are not available for the day to day running of the charity. At the financial year-end, the charity held designated reserves of £9,996,527 (2023: £10,360,651). In the event of a child's death, the funds will be available to the family to support funeral and related costs and then the balance will be released from designated children's funds after a period of a year. Following the end of a successful course of treatment, and a child exhibiting no evidence of disease (NED), funds will remain designated for a period of five years so that they are available for that child should they suffer a relapse and require further treatment or pastoral support, a situation which is sadly common for neuroblastoma patients. This policy resulted in £84,627 (2023: £280,187) transferring from designated children's funds within the year, 70% transferred to the designated Solving Kids' Cancer UK Research Fund; 10% to the designated Solving Kids' Cancer UK Children's Reserve Fund; 10% to the Pastoral Grant Fund and 10% to undesignated reserves.

Restricted Reserves are funds which can only be used for particular restricted purposes within the objects of the charity and arise when specified by the donor, or when funds are raised for particular restricted purposes. At the financial year-end, the charity held restricted reserves of £2,064,050 (2022: £2,012,688), of which £1,177,426 (2023: £1,228,877) relates to funds being held on behalf of families who were previously supported by Families Against Neuroblastoma.

Supporters of the charity are asked to note that, although the charity appears to hold significant reserves, 77% of these funds are designated or restricted to fund the treatment or support of children and families, and a further 5% is designated or restricted to Research.

Risk management

The charity's Trustees have considered the major risks to which the charity is exposed and have reviewed those risks and established systems and procedures to manage those risks. The Trustees have overall responsibility for ensuring that the charity has an appropriate system of controls, financial and otherwise. They are responsible for safeguarding the assets of the charity and for taking reasonable steps for the prevention and detection of fraud and other irregularities and to provide reassurance that:

- its assets are safeguarded against unauthorised use or disposition;
- proper records are maintained and financial information used within the charity or for publication is reliable and reviewed at every Trustee meeting; and
- the charity complies with relevant laws and regulations.

The risk register is a live document which is reviewed in detail every six months by the Board and Leadership Team.

Risk categories include:

Governance
Covers risk of non-delivery of strategy, Board skills & capabilities and effective decision-making and reporting.

Controls in place to manage these risks include a clear strategy underpinned by annual plans, and a balanced and involved Board who have clear terms of reference and consider their effectiveness and undertake training as appropriate. The Board requests and receives regular reporting from executive management.

People
Covers risk of loss of key staff and poor structure.

Controls in place to manage these risks include strong oversight by CEO and senior managers, clear roles and responsibilities and strong HR processes. As staff numbers are small, this is a key risk which is closely monitored.

Finance
Covers all financial risks around effectiveness of our business model, level of reserves, management of investments and effective insurance.

Controls in place to manage these risks include annual budgeting and forecasting processes with regular reporting of our financial position to Trustees. We have a clear reserves policy and hold general reserves to manage any changes in cash flow. We have an investment policy and investment managers who report on performance regularly.

Compliance
Covers all risks relating to non-compliance of required regulations including data protection, health and safety, employment and financial.

Controls in place to manage these risks include effective policies, staff training and awareness and effective advisors.

Operational, legal and physical
Covers risk of not being able to meet demands for family support and quality of support provided; risk of lack of funds due to expenditure exceeding income; health and safety risks and other operational risks including employment risks and disaster recovery.

Controls in place to manage these risks include ensuring the team have appropriate support to deliver in their roles and we are continuously considering current and future demand. Budgets and reserves are effectively managed to ensure funding is maintained. We have policies in place which are well understood and adhered to around health and safety, disaster recovery, employment policies and other areas of compliance.

Environmental / external factors
Covers reputational risk and relevant external risks such as economic conditions and Brexit.

Controls in place to manage these risks include effective communications policies and resource and ongoing monitoring of relevant external plans with action plans as required.

Our finances

Continued

Grant-making policy

The Board of Trustees makes two types of grants. Firstly, small grants to assist children living with neuroblastoma. Families who wish to apply, either self-refer, hear about the charity from their child's oncologist, or contact the charity's Family Support Team. Grants are also offered in the form of a hardship fund for families struggling to meet their necessary costs due to the effects of having a child in treatment for neuroblastoma.

The second type is research grants. We engage in two distinct research funding mechanisms: a regular competitive funding call, and also ad-hoc exceptional funding requests. All research grants are awarded in line with the principles laid out by the Association of Medical Research Charities (AMRC). Each application will be subject to rigorous scientific review guided by the charity's Scientific Advisory Board (SAB) and the nature of any grant made will depend on funds available through Solving Kids' Cancer UK's own reserves, or those made available through strategic collaborative partnerships.

Investment policy and objectives

The Deed of Trust allows the charity to deposit or invest funds in any manner; but to do so only after obtaining such advice from financial experts as the Trustees deem necessary and having regard to the suitability of investments and need for diversification. The charity aims to follow the COIF Ethical Fund Policy; excluding investments in companies involved in, for example, nuclear weapons, landmines, production of abortifacients, and other disqualifying criteria where there is a significant involvement (>10% of turnover).

Fundraising approach and policy

As a cause-related charity, we recognise that the service we offer for children and families affected by neuroblastoma and the advances in research we invest in, would not be possible without the generous support and passion our supporters, and families' supporters provide. We receive very little public funding for our work, relying on the generous support of the neuroblastoma community and general public.

We are registered with the regulatory body for fundraising in the UK, the Fundraising Regulator. As members of the scheme, we follow their Code of Fundraising Practice and comply with the key principles embodied in The Code. Many of our families raise funds for us at a local level and we ensure that they have all the information they need to comply with our policies and procedures.

It is hugely important to us that our supporters trust us and are well looked after:

- We ensure that we never put undue pressure on members of the public when raising funds.
- We are open and honest and approach our fundraising activities respectfully and considerately.
- We ensure that we comply with the wishes of our donors and comply with all general data protection laws.
- We respect the rights, dignity and privacy of our supporters and beneficiaries.
- We are accountable to our supporters and take this responsibility seriously.

We review all of our fundraising campaigns to ensure they fully comply with The Code and our fundraising activities are discussed regularly at Board meetings, to help ensure that our fundraising practices reflect and reinforce our values. Whether we're fundraising ourselves or working with families, organisations or volunteers, it's just as important.

We currently raise funds in a variety of ways, including regular and individual giving programmes, challenge events, SKC-run and third party events, corporate partnerships, direct cash donations, raffles, sponsored events and Charity of the Year partnerships. We are performing well against our five-year fundraising strategy, which is building upon our strong stewardship approach to develop existing income streams and develop new ones.

Within the year, we achieved an undesignated income of £1,003,793 with 30% coming from Corporates, Trusts, Third Party Events and Major Gifts, 27% from Community and Events and 27% coming through investment income. Our performance reflects our strong and evolving strategy.

We take the protection of the personal data of all our supporters and donors extremely seriously, and constantly review and monitor our fundraising policies and procedures to ensure we deliver 'best practice'. We do not engage professional fundraisers to raise money on our behalf. We use our CRM system to further protect and manage our supporter data.

We welcome feedback on our fundraising activities at any time and strive to listen and learn from this feedback. During the year, we recorded one complaint. We have a robust complaints policy. If a complaint about our fundraising activities is unable to be resolved through our complaint's procedure, members of the public are advised to raise it with the Fundraising Regulator.

Trustees' responsibilities statement

The Trustees (who are also the Directors of Solving Kids' Cancer UK for the purposes of company law) are responsible for preparing the Trustees Annual Report and the financial statements in accordance with applicable law and regulations.

Company law requires the Trustees' to prepare financial statements for each financial year. Under that law, the Trustees have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law, the Trustees must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and the income and expenditure of the company for that period.

In preparing these financial statements, the Trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgements and accounting estimates that are reasonable and prudent; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in operation.

The Trustees are responsible for keeping adequate accounting records that are sufficient to show and explain the company's transactions and disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Each of the persons who is a Trustee at the date of approval of this report confirms that:

- so far as each Trustee is aware, there is no relevant audit information of which the company's auditor is unaware; and
- each Trustee has taken all steps that they ought to have taken as a Trustee to make themselves aware of any relevant audit information and to establish that the company's auditor is aware of that information.

This report has been prepared in accordance with the provisions applicable to companies entitled to the small companies' exemption.

Registered office:
Signed on behalf of the Board of Trustees
Unit 02-03 Salisbury House,
29 Finsbury Circus,
London EC2M 7AQ

David Coulon
Trustee and Treasurer
26th September 2024

Independent Auditor’s Report

Independent Auditor’s Report to the Trustees and members of Solving Kids’ Cancer UK

Opinion

We have audited the financial statements of Solving Kids’ Cancer UK (“the charitable company”) for the year ended 31 March 2024 which comprise the Statement of Financial Activities (incorporating the Income and Expenditure Account), the Balance Sheet, the Statement of Cash Flows and the related notes, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including The Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

- give a true and fair view of the state of the charitable company’s affairs as at 31 March 2024 and of its incoming resources and application of resources, including its income and expenditure, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006, the Charities and trustees Investment (Scotland) Act 2005 and regulation 8 of the Charities Accounts (Scotland) Regulations 2006.

Basis for Opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the auditor’s responsibilities for the audit of the financial statements section of our report. We are independent of the charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC’s Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions Relating to Going Concern

In auditing the financial statements, we have concluded that the trustees’ use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the Solving Kids’ Cancer UK’s ability to continue as a going concern for a period of at least 12 months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

Other Information

The other information comprises the information included in the annual report, other than the financial statements and our auditor’s report thereon. The trustees are responsible for the other information. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

Opinion on Other Matters Prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

- The information given in the Trustees’ Annual Report, which includes the directors’ report prepared for the purposes of company law, for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- The directors’ report included within the Trustees’ Annual Report has been prepared in accordance with applicable legal requirements.

Matters on which we are required to report by exception

In the light of the knowledge and understanding of the charitable company and its environment obtained in the course of the audit, we have not identified material misstatements in the directors’ report included within the Trustees’ Annual Report.

We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 and the Charities Accounts (Scotland) Regulations 2006 require us to report to you if, in our opinion:

- adequate and proper accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or
- the financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of Trustees’ remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit; or
- the Trustees were not entitled to prepare the financial statements in accordance with the small companies regime and take advantage of the small companies’ exemptions in preparing the Trustees’ report and from the requirement to prepare a strategic report.

Responsibilities of Trustees

As explained more fully in the trustees’ responsibilities statement, the trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the charitable company’s ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so.

Auditor’s Responsibilities for the Audit of the Financial Statements

We have been appointed as auditor’s under section 44(1)(c) of the Charities and Trustee Investment (Scotland) Act 2005 and under the Companies Act 2006 and report in accordance with the Acts and relevant regulations made or having effect thereunder.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud.

The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

- We obtained an understanding of the charitable company’s activities, controls and laws and regulations and assessed the susceptibility of the charitable company’s financial statements to material misstatement from irregularities, including fraud.

Independent Auditor's Report

Continued

- We determined that the laws and regulations that are most significant to the charitable company are the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102), the Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (Charities SORP (FRS 102)), Companies Act 2006, Charities Act 2011, Charities and Trustee Investment (Scotland) Act 2005, the Fundraising Regulations and the charitable company's Articles of Association.
- Based on this understanding we designed our audit procedures to detecting irregularities, including fraud. Testing undertaken included making enquiries on the management and those charged with governance; journal entry testing; review of bank letters, investments reports, trustee board minutes and the Articles of Association; review of transactions for any undisclosed related party transactions; reviewing financial statement disclosures and testing of supporting documentation to assess compliance with applicable laws and regulations. These procedures were designed to provide reasonable assurance that the financial statements were free from fraud or error.

As part of an audit in accordance with ISAs (UK), we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Trustees.
- Conclude on the appropriateness of the trustees' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the charitable company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the charitable company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Use of our report

This report is made solely to the charitable company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006, and to the charitable company's trustees, as a body, in accordance with Regulation 10 of the Charities Accounts (Scotland) Regulations 2006. Our audit work has been undertaken so that we might state to the charitable company's members and trustees those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company, the charitable company's members as a body and the charitable company's trustees as a body, for our audit work, for this report, or for the opinions we have formed.

Tim Hardy (Senior Statutory Auditor)
26th September 2024
For and on behalf of SHIPLEYS LLP
Chartered Accountants & Statutory Auditor
10 Orange Street, Haymarket, London WC2H 7DQ

Statement of financial activities

(incorporating the income and expenditure account) year ended 31 March 2024

	Note	General Funds Undesignated £	General Funds Designated £	Restricted funds £	Total Funds 2024 £	Total Funds 2023 £
INCOME						
Donations	2	706,171	1,259,095	131,361	2,096,627	2,764,305
Trading activities	3	22,563	26,427	150	49,140	44,510
Investment income	4	275,059	-	55,564	330,623	182,709
TOTAL INCOME		1,003,793	1,285,522	187,075	2,476,390	2,991,524
EXPENDITURE ON:						
Raising funds	5	(323,918)	(17,207)	(1,053)	(342,178)	(321,106)
Charitable activities	6	(777,113)	(1,972,911)	(134,660)	(2,884,684)	(1,563,745)
TOTAL EXPENDITURE		(1,101,031)	(1,990,118)	(135,713)	(3,226,862)	(1,884,851)
NET (EXPENDITURE) / INCOME BEFORE GAINS / (LOSSES) ON INVESTMENTS		(97,238)	(704,596)	51,362	(750,472)	1,106,673
Net gains / (losses) on investments	13	–	345,776	–	345,776	(184,680)
Other (losses) / gains		(22,547)	3,159	–	(19,388)	43,684
NET (EXPENDITURE) / INCOME		(119,785)	(355,661)	51,362	(424,084)	965,677
Transfer between funds	20,21,22	8,463	(8,463)	–	–	–
NET MOVEMENT IN FUNDS		(111,322)	(364,124)	51,362	(424,084)	965,677
RECONCILIATION OF FUNDS						
Total funds brought forward		959,981	10,360,651	2,012,688	13,333,320	12,367,643
TOTAL FUNDS CARRIED FORWARD		848,659	9,996,527	2,064,050	12,909,236	13,333,320

The Statement of financial activities includes all gains and losses in the year. All of the above amounts relate to continuing activities.
The notes on pages 38-59 form part of these financial statements.

Balance sheet

Year ended 31 March 2024

	Note	2024 £	2024 £	2023 £	2023 £
FIXED ASSETS					
Tangible assets	12		6,722		8,976
Investments	13		3,865,164		3,519,388
			3,871,886		3,528,364
CURRENT ASSETS					
Debtors	14	228,021		100,921	
Cash at bank and in hand		11,396,820		11,284,479	
		11,624,841		11,385,400	
CREDITORS					
Amounts falling due within one year	15	(1,205,625)		(1,022,050)	
NET CURRENT ASSETS			10,419,216		10,363,350
TOTAL ASSETS LESS CURRENT LIABILITIES			14,291,102		13,891,714
CREDITORS:					
Amounts falling due after one year	16		(1,381,866)		(558,394)
NET ASSETS			12,909,236		13,333,320
FUNDS OF THE CHARITY					
Restricted funds	20		2,064,050		2,012,688
Designated funds	21		9,996,527		10,360,651
Undesignated funds	22		848,659		959,981
TOTAL FUNDS CARRIED FORWARD			12,909,236		13,333,320

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime. These financial statements were approved by the members of the committee and authorised for issue on 26th September 2024 and are signed on their behalf by:

David Coulon, Trustee
Company registration number: 07208648

The notes on pages 38-59 form part of these financial statements.

Statement of cash flows

Year ended 31 March 2024

	Note	2024 £	2023 £
CASH FLOWS FROM OPERATING ACTIVITIES			
Net income		(424,084)	965,677
Adjustments for:			
Depreciation		6,007	5,508
Losses / (gains) on investments		(345,776)	184,680
Dividends and interest from investments		(330,623)	(161,742)
Loss on sale of fixed assets		72	-
(Decrease) / increase in debtors		(131,672)	119,512
(Decrease) / increase in creditors		1,007,047	(101,031)
Net cash provided by operating activities		(219,029)	1,012,604
CASH FLOWS FROM INVESTING ACTIVITIES			
Dividends and interest from investments		335,195	157,068
Purchase of property, plant and equipment		(3,825)	(5,234)
Net cash provided by investing activities	28	331,370	151,834
CHANGE IN CASH AND CASH EQUIVALENTS	28	112,341	1,164,438
CASH AT START OF YEAR	28	11,284,479	10,120,041
CASH AT END OF YEAR		11,396,820	11,284,479

The notes on pages 38-59 form part of these financial statements.

Notes to the financial statements

1. Accounting policies

General information
Solving Kids' Cancer UK Ltd is a private company limited by guarantee incorporated in England under the Companies Act. The address of the registered office is Unit 02-03 Salisbury House, 29 Finsbury Circus, London EC2M 7AQ. The objectives of the charity are set out on page 23.

On 25 August 2023, the charitable company changed its name from Solving Kids' Cancer UK Ltd to Solving Kids' Cancer UK.

Basis of preparation
The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) - (Charities SORP (FRS 102)), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006.

Solving Kids' Cancer UK meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policies.

The functional currency of the charity is considered to be pounds sterling because that is the currency of the primary economic environment in which the charity operates. The financial statements are also presented in pounds sterling.

The amounts in the financial statements are presented to the nearest £, unless otherwise stated.

Preparation of the financial statements on a going concern basis
The financial statements of the charity have been prepared on the going concern basis. There are no material uncertainties about the charity's ability to continue. The trustees consider that the going concern basis is appropriate having considered a period of at least twelve months from approval of these financial statements. The trustees have prepared budgets and cash flow forecasts for that period which support the going concern assumption.

Fund accounting
Undesignated funds are available to spend on activities that further any of the purposes of charity.

Designated funds are funds of the charity which the Trustees have decided at their discretion to set aside to use for a specific purpose.

Restricted funds are donations which the donor has specified are to be solely used for particular restricted purposes within the objects of the charity.

Income
Income is recognised when the charity has entitlement to the funds, any performance conditions attached to the item of income have been met, it is probable that the income will be received and the amount can be measured reliably.

Donations are recognised when the charity has been notified in writing of both the amount and settlement date. In the event that a donation is subject to conditions that require a level of performance before the charity is entitled to the funds, the income is deferred and not recognised until either those conditions are fully met, or the fulfilment of those conditions is wholly within the control of the charity and it is probable that those conditions will be fulfilled in the reporting period.

90% of any donation made to an individual appeal or journey is designated for the particular purpose of funding treatment not freely available on the NHS. The remaining 10% is retained within undesignated general funds to cover costs associated with the administration and management of appeals and journeys; including support with fundraising, logistics, and development of relationships as intermediary between families and the medical institutions that provide access to treatments and clinical trials.

Donated professional services and donated facilities are recognised as income when the charity has control over the item, any conditions associated with the donated item have been met, the receipt of economic benefit from the use by the charity of the item is probable and that economic benefit can be measured reliably. On receipt, donated professional services and donated facilities are recognised on the basis of the value of the gift to the charity which is the amount the charity would have been willing to pay to obtain services or facilities of equivalent economic benefit on the open market; a corresponding amount is then recognised in expenditure in the period of receipt.

Income from Government and other grants, whether 'capital' grants or 'revenue' grants, is recognised when the charity has entitlement to the funds, any performance conditions attached to the grants have been met, it is probable that the income will be received and the amount can be measured reliably and is not deferred. In respect of the Coronavirus Job Retention Scheme grant; all conditions, with respect to the eligible costs being claimed, need to be met.

Interest on funds held on deposit is included when receivable and the amount can be measured reliably by the charity; this is normally upon notification of the interest paid or payable by the Bank.

Dividends are recognised once the dividend has been declared and notification has been received of the dividend due. This is normally upon notification by our investment advisor of the dividend yield of the investment portfolio.

Expenditure and irrecoverable VAT
Expenditure is recognised once there is a legal or constructive obligation to make a payment to a third party, it is probable that settlement will be required and the amount of the obligation can be measured reliably. All expenditure is accounted for on an accruals basis.

Expenditure is classified under the following activity headings:

- Costs of raising funds comprise the costs of attracting donations and fundraising.
- Expenditure on charitable activities includes the cost incurred by the charity in the delivery of activities and services for its beneficiaries.

Grants payable are payments made to third parties in the furtherance of the charitable objects of the charity. In the case of an unconditional grant offer this is accrued once the recipient has been notified of the grant award. The notification gives the recipient a reasonable expectation that they will receive the grant. Grant awards that are subject to the recipient fulfilling performance conditions are only accrued when the recipient has been notified of the grant and any remaining unfulfilled condition attaching to that grant is outside of the control of the charity.

Provisions for grants are made when the intention to make a grant has been communicated to the recipient but there is uncertainty as to the timing of the grant or the amount of grant payable.

Support costs are those functions that assist the work of the charity but do not directly undertake charitable activities. Support costs include staff, premises, legal and professional, finance, depreciation and governance costs. These costs have been allocated between cost of raising funds and expenditure on charitable activities on the basis of an estimate of the proportion of time spent by staff on those activities.

Governance costs comprise all costs involving the public accountability of the charity and its compliance with regulation and good practice.

Irrecoverable VAT is charged as a cost against the activity for which the expenditure was incurred.

Tangible fixed assets
Fixed assets are capitalised at cost and are depreciated over their estimated useful economic lives on a straight line basis as follows:
Equipment – 25% on straight line basis.

Fixed asset investments
Investments are a form of basic financial instrument and are initially recognised at their transaction value and subsequently measured at their fair value as at the balance sheet date using the closing quoted market price.

All gains and losses are taken to the Statement of Financial Activities as they arise. Realised gains and losses on investments are calculated as the difference between sales proceeds and their opening carrying value or their purchase value if acquired subsequent to the first day of the financial year. Unrealised gains and losses are calculated as the difference between the fair value at the year end and their carrying value. Realised and unrealised investment gains and losses are combined in the Statement of Financial Activities.

.

Notes to the financial statements Continued

Debtors
Trade and other debtors are recognised at the settlement amount due after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

Cash at bank and in hand
Cash at bank and cash in hand includes cash and short term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account.

Creditors and provisions
Creditors and provisions are recognised where the charity has a present obligation resulting from a past event that will probably result in the transfer of funds to a third party and the amount due to settle the obligation can be measured or estimated reliably. Creditors and provisions are normally recognised at their settlement amount after allowing for any trade discounts due

Financial instruments
The charity only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value with the exception of bank loans which are subsequently measured at amortised cost using the effective interest method.

Operating leases
The charity classifies the lease of the office space as an operating lease as the title remains with the lessor. Rental charges are charged on a straight line basis over the term of the lease

Pension costs
Contributions to defined contribution plans are recognised as an expense in the period in which the related service is provided. Differences between contributions payable in the year and the contributions actually paid are shown as either accruals or prepayments on the balance sheet.

2. Donations

	Undesignated funds **£**	**Designated funds** **£**	**Restricted funds** **£**	**Total funds 2024** **£**
Donations	**657,671**	**1,259,095**	**44,713**	**1,961,479**
Donated services	**48,500**	**-**	**-**	**48,500**
Government grants	**-**	**-**	**86,648**	**86,648**
	706,171	**1,259,095**	**131,361**	**2,096,627**

	Undesignated funds £	Designated funds £	Restricted funds £	Total funds 2023 £
Donations	533,973	1,602,591	493,919	2,630,483
Donated services	35,071	-	-	35,071
Government grants	-	-	98,751	98,751
	569,044	1,602,591	592,670	2,764,305

The charity benefits greatly from the involvement and enthusiastic support of its many volunteers. In accordance with FRS 102 and Charities SORP (FRS 102), the economic contribution of general volunteers is not recognised in the financial statements.

During the year, the charity received donated services relating to legal services and support for the Neuroblastoma Parent Global Symposium. The value of these services to the charity is estimated at £38,500 and £10,000 respectively (2023: £25,071 and £10,000 respectively). The estimated value of these services is recognised within income as a donation with an equivalent expense through the Statement of Financial Activities.

Income from Government grants comprises grants received under the UK Government COVID Medical Research Charity Support Fund of £86,648 (2023: £98,751) to provide support to UK Research. The charity has not benefited from any other kinds of government assistance during the current or prior year.

3. Other trading activities

	Undesignated funds **£**	**Designated funds** **£**	**Restricted funds** **£**	**Total funds 2024** **£**
Fundraising events	**22,563**	**26,427**	**150**	**49,140**

	Undesignated funds £	Designated funds £	Restricted funds £	Total funds 2023 £
Fundraising events	29,265	11,445	3,800	44,510

Notes to the financial statements Continued

4. Investment income

	Undesignated funds	**Designated funds**	**Restricted funds**	**Total funds 2024**
	£	**£**	**£**	**£**
Income from investments	**108,084**	**-**	**-**	**108,084**
Deposit account interest	**166,975**	**-**	**55,564**	**222,539**
	275,059	**-**	**55,564**	**330,623**

	Undesignated funds	Designated funds	Restricted funds	Total funds 2023
	£	£	£	£
Income from investments	107,438	-	-	107,438
Deposit account interest	54,304	-	20,967	75,271
	161,742	-	20,967	182,709

5. Cost of raising funds

	Undesignated funds	**Designated funds**	**Restricted funds**	**Total funds 2024**
	£	**£**	**£**	**£**
Cost of raising funds	**215,334**	**17,207**	**1,053**	**233,594**
Support costs	**108,584**	**-**	**-**	**108,584**
	323,918	**17,207**	**1,053**	**342,178**

	Undesignated funds	Designated funds	Restricted funds	Total funds 2023
	£	£	£	£
Cost of raising funds	188,963	17,978	1,781	208,722
Support costs	112,384	-	-	112,384
	301,347	17,978	1,781	321,106

6. Costs of charitable activities

	Activities undertaken directly	**Grant funding activities**	**Support costs**	**Total funds 2024**
	£	**£**	**£**	**£**
Support	**221,888**	**815,939**	**119,853**	**1,157,680**
Research	**153,089**	**1,262,051**	**92,022**	**1,507,162**
Awareness	**134,291**	**-**	**85,551**	**219,842**
	509,268	**2,077,990**	**297,426**	**2,884,684**

	Activities undertaken directly	Grant funding activities	Support costs	Total funds 2023
	£	£	£	£
Support	181,279	807,590	123,667	1,112,536
Research	135,806	38,765	88,152	262,723
Awareness	117,548	-	70,938	188,486
	434,633	846,355	282,757	1,563,745

Expenditure on charitable activities was £2,884,684 (2023: £1,563,745) of which £777,113 was undesignated (2023: £561,581), £1,972,911 was designated (2023: £755,452) and £134,660 was restricted (2023: £246,712).

Notes to the financial statements Continued

7. Analysis of support costs

Support costs are allocated based on the proportion of time spent by staff on those activities.

	Support	**Research**	**Awareness**	**Fundraising activities**	**Total funds 2024**
	£	**£**	**£**	**£**	**£**
Staff costs	**63,519**	**48,769**	**45,340**	**57,547**	**215,175**
Premises	**32,491**	**24,946**	**23,192**	**29,436**	**110,065**
Legal and professional	**3,458**	**2,655**	**2,468**	**3,133**	**11,714**
Finance costs	**774**	**594**	**552**	**701**	**2,621**
Depreciation	**1,773**	**1,362**	**1,266**	**1,606**	**6,007**
Governance costs	**17,838**	**13,696**	**12,733**	**16,160**	**60,427**
	119,853	**92,022**	**85,551**	**108,583**	**406,009**

	Support	Research	Awareness	Fundraising activities	Total funds 2023
	£	£	£	£	£
Staff costs	54,224	38,652	31,104	49,277	173,257
Premises	42,579	30,351	24,424	38,694	136,048
Legal and professional	9,931	7,079	5,697	9,025	31,732
Finance costs	812	579	466	739	2,596
Depreciation	1,724	1,229	989	1,566	5,508
Governance costs	14,397	10,262	8,258	13,083	46,000
	123,667	88,152	70,938	112,384	395,141

8. Governance costs

	2024	2023
	£	£
Auditor's Remuneration	**13,000**	13,000
Legal and professional	**39,828**	26,437
Staff costs	**7,599**	6,563
	60,427	46,000

9. Analysis of grants

	2024	2023
	£	£
Children's treatment	**639,537**	685,390
Family support	**176,402**	122,200
Research		
University of Birmingham	**626,321**	38,378
University of Southampton	**159,827**	-
St Jude Hospital	**469,129**	-
Newcastle University	**-**	(912)
University College London	**-**	(1,001)
Redmapp	**2,500**	-
Travel bursary	**4,274**	2,300
	2,077,990	846,355

Children's treatment grants are made towards the medical costs of the children suffering from neuroblastoma. The grants are paid directly to the hospitals providing the treatment.

Family Support Grants are those made towards providing essential support services to families affected by affected by neuroblastoma. These grants are paid directly to affected families and organisations as appropriate or as directed.

Grants are made towards medical research for potential future life-saving treatments made possible through the constantly evolving world of burgeoning laboratory, pre-clinical and clinical research. These grants are paid directly to the institutions that are working internationally, reflecting the specialist and global nature of the research we fund.

Notes to the financial statements Continued

10. Staff costs and emoluments

	2024	2023
	£	£
Wages and salaries	**676,290**	581,282
Social security costs	**58,664**	55,767
Pension costs – defined contribution	**24,871**	19,280
	759,825	656,329

Pension costs are allocated to activities in proportion to the related staffing costs and are allocated between undesignated, designated and restricted funds on the basis of each employee's activities.

Particulars of employees: The average head count of employees during the year was 19 (2023: 18). The average number of full-time equivalent employees during the year is analysed as follows:

	2024	2023
	No.	No.
Charitable activities	**8**	7
Fundraising	**3**	3
Support	**4**	4
	15	14

The number of employees whose remuneration for the year fell within the following bands, were:

	2024	2023
	No.	No.
£60,000 to £69,999	**1**	-
£80,000 to £89,999	**1**	1

No higher paid staff were accruing benefits under a pension scheme (2023: None).

11. Net income Net income is stated after charging:

	2024	2023
	£	£
Auditor's remuneration		
Audit	**13,000**	13,000
Taxation	**-**	804
Depreciation	**6,007**	5,508
Operating leases – offices	**6,925**	8,593

12. Tangible fixed assets

	Equipment
	£
Cost	
At April 2023	**28,572**
Additions	**3,825**
Disposals	**(4,555)**
At 31 March 2024	**27,842**
DEPRECIATION	
At 1 April 2023	**19,596**
Charge for the year	**6,007**
Disposals	**(4,483)**
At 31 March 2024	**21,120**
NET BOOK VALUE	
At 31 March 2024	**6,722**
At 31 March 2023	**8,976**

Notes to the financial statements Continued

13. Investments

Movement in market value	2024 £	2023 £
Market Value at 1 April 2023	**3,519,388**	3,704,068
Net gain / (loss) on revaluation	**345,776**	(184,680)
Market value at 31 March 2024	**3,865,164**	3,519,388
Historical cost at 31 March 2024	**2,500,000**	2,500,000

Analysis of investments as at 31 March 2024	Designated funds 2024 £	Designated funds 2023 £
UK listed investments	**3,865,164**	3,519,388

All investments are carried at their fair value. Holdings in investment funds, unit trusts and open-ended investment companies are at the bid price. The basis of fair value for quoted investments is equivalent to the market value, using the bid price. Asset sales and purchases are recognised at the date of trade at cost (that is their transaction value).

The following investments were material in the context of the investment portfolio:

COIF Charities Ethical Investment Fund - £3,865,164 (2023: £3,519,388).

The main form of financial risk faced by the charity is that of volatility in investment markets due to wider economic conditions and variability of investment returns. This risk is mitigated by obtaining advice from a financial expert on the charity's investment portfolio.

14. Debtors

	2024 £	2023 £
Other debtors	**16,620**	10,869
Prepayments and accrued income	**211,401**	90,052
	228,021	100,921

15. Creditors

Amounts falling due within a year	2024 £	2023 £
Trade creditors	**2,328**	247
Other creditors	**-**	8,183
Accruals and deferred income	**154,103**	149,465
Grant commitments (note 17)	**501,136**	242,613
Funds held as agent (note 18)	**548,058**	621,542
	1,205,625	1,022,050

16. Creditors

Amounts falling due after more than one year	2024 £	2023 £
Grant commitments (note 17)	**1,381,866**	558,394

Grant commitments of £153,976 are due in more than five years (2023: £153,976).

17. Grant commitments

	2024 £	2023 £
Grant commitments brought forward	**801,007**	969,960
New commitments during the year	**1,262,051**	38,766
Payments made in the year	**(180,056)**	(207,719)
Grant commitments carried forward	**1,883,002**	801,007

Commitments at 31 March 2024 are payable as follows:		
Within one year	**501,136**	242,613
After more than one year	**1,381,866**	558,394
Grant commitments carried forward	**1,883,002**	801,007

18. Funds held as agent

	2024 £	2023 £
Funds held as agent brought forward	**621,542**	602,488
Funds received during the year	**56,637**	90,000
Payments made	**(130,121)**	(70,946)
Funds held as agent carried forward	**548,058**	621,542

The charity has received funds as agent in its role as administrator of the Request for Applications (RFA) process and also of the research project for the prospective identification of children with “ultra-high-risk” (UHR) neuroblastoma.

At the year end, the charity held £548,058 (2023: £621,542) and this has been included in creditors in Note 15. £361,698 was held on behalf of Zoe4Life (2023: £392,604), £143,292 on behalf of The Merryn Lacy Trust (2023: £174,198) and £43,068 on behalf of Joining Against Cancer in Kids (J-A-C-K) (2023: £54,740).

19. Commitments under operating leases

At 31 March 2024 the company had total minimum lease payments under non-cancellable operating leases as set out below.

Land and buildings	2024 £	2023 £
Operating leases which expire:		
Within 1 year	**1,484**	1,619
Within 2 to 5 years	**-**	1,484
	1,484	3,103

20. Restricted funds

	Balance at 1 April 2023 £	Income £	Expenditure £	Transfers £	Balance at 31 March 2024 £
Families Against Neuroblastoma (FAN)	**938,184**	**41,819**	**(35,965)**	**(71,050)**	**872,988**
FAN Emergency Relapse Fund	**290,693**	**13,745**	(71,050)	**71,050**	**304,438**
HK Fund	**5,919**	-	(5,919)	-	-
CE Discretionary Fund	**238**	-	(238)	-	-
Restricted research funds	**46,590**	**792**	(5,364)	-	**42,018**
Other funds	**150,634**	**117,479**	(11,062)		**257,051**
Joining Against Cancer in Kids	**27,180**	-	(1,540)	-	**25,640**
Sunni Mae Fund	**84,365**	-	-	-	**84,365**
Merryn Lacy Fund	**100,570**	-	-	-	**100,570**
Lottery funding	**6,139**	-	(3,320)	-	**2,819**
Rupert’s Revenge Trust Fund	**148,169**	**735**	(13)	-	**148,891**
ALADDIN	**7,160**	-	-	-	**7,160**
Isla Caton Fund	**206,847**	**2,505**	(46)	-	**209,306**
Ireland	-	**10,000**	(1,196)	-	**8,804**
	2,012,688	**187,075**	**(135,713)**	-	**2,064,050**

Notes to the financial statements Continued

20. Restricted funds (continued)

	Balance at 1 April 2022 £	Income £	Expenditure £	Transfers £	Balance at 31 March 2023 £
Families Against Neuroblastoma (FAN)	932,614	16,488	(10,918)	-	938,184
FAN Emergency Relapse Fund	286,208	4,485	-	-	290,693
HK Fund	15,842	-	(9,923)		5,919
CE Discretionary Fund	3,782	-	(3,544)	-	238
Restricted research funds	45,534	1,078	(22)	-	46,590
Parent Conference fund	834	28,979	(29,813)		-
Other funds	96,815	55,324	(1,505)	-	150,634
Joining Against Cancer in Kids	27,180	-	-	-	27,180
Sunni Mae Fund	84,365	-	-	-	84,365
Family Support fund	25,000	-	(25,000)	-	-
Support bags	25,000	-	(25,000)	-	-
Merryn Lacy Fund	100,570	-	-	-	100,570
Lottery funding	-	9,660	(3,521)	-	6,139
Rupert's Revenge Trust Fund	-	248,191	(100,022)	-	148,169
ALADDIN	-	46,181	(39,021)		7,160
Isla Caton Fund	-	207,051	(204)		206,847
	1,643,744	617,437	(248,493)	-	2,012,688

Restricted funds

Restricted funds can only be used for particular restricted purposes within the objects of the charity as specified by the donor or when funds are raised for particular restricted purposes.

Families Against Neuroblastoma (FAN)/ FAN Emergency Relapse Fund There are 10 funds transferred from Families Against Neuroblastoma (FAN) and held for the sole use of individual children for access to treatment and welfare / pastoral issues. Treatments are limited to those that are consistent with Solving Kids' Cancer UK Clinical Trial Policy. A further two donations from FAN were received to be used solely to support children with relapsed neuroblastoma with no access to other funds to pay for treatment that is not freely available on the NHS.

HK Fund is restricted for the sole purposes of supporting an individual named child. In accordance with the wishes of the donor, the fund supports the long-term health and welfare related needs of the beneficiary, and is not accessed on a regular basis.

CE Discretionary Fund was established through an individual donation made to the charity to provide the Chief Executive with a means to fund initiatives in support of the effective working of the organisation, but for which no other budget existed.

Restricted research funds is a restricted fund where monies are not currently awarded to any specific research project, but nonetheless earmarked to support research.

Parent conference fund represents donations towards the annual parent conference.

Other Funds represent funds created by families in memoriam specifically for research and advocacy projects.

Joining Against Cancer in Kids is a restricted fund which has been provided by Joining Against Cancer in Kids to support the costs incurred by families when participating in neuroblastoma trials/treatment being conducted at The Memorial Sloan Kettering Cancer Centre, New York or Hospital Saint Joan de Déu Barcelona.

Sunni Mae Fund is restricted to support the development and operational running of a Solving Kids' Cancer UK's presence in Ireland and / or provide wider support to Irish families affected by Neuroblastoma. Alternatively, the fund can be used to support a future research funding call in which The Sunni Mae Trust will be acknowledged as a named collaborative funding partner.

Family support fund is restricted to the activities of the family support team.

Support bags represents funds donated specifically to create Support bags for all children diagnosed with Neuroblastoma.

Merryn Lacy Fund represents funds donated by the trust which are restricted to Research.

Lottery funding represents a National Lottery Awards For All grant restricted to our family support Life after Cancer Programme.

Rupert's Revenge Trust Fund represents restricted funds of £100,000 towards the Anti-CD47 + anti-GD2 research and £148,169 restricted to Research.

ALADDIN represents a European funding grant for the delivery of a multi-stakeholder educational programme on regulatory science in paediatric cancer drug development.

Isla Caton Fund represents funds transferred and raised for pioneering research in memory of beautiful Isla who loved to sing and dance.

Ireland represented funds provided to the charity from a donor specifically to support the registration of the charity in Ireland to enable wider support of families in Ireland.

Notes to the financial statements Continued

21. Designated funds

	Balance at 1 April 2023	Income	Expenditure	Transfers	Net gains on investments	Other gains and losses	Balance at 31 March 2024
	£	£	£	£	£	£	£
Designated Funds	**7,385,497**	**1,196,884**	**(671,965)**	**(84,627)**	-	-	**7,825,789**
Solving Kids' Cancer Children's Reserve Fund	**619,431**	-	**(26,737)**	**8,463**	-	-	**601,157**
Solving Kids' Cancer Research Fund	**1,310,972**	**88,300**	**(1,277,757)**	**59,238**	-	**3,159**	**183,912**
Family Support Fund	**1,399**	-	-	-	-	-	**1,399**
Covid-19 Fund	**143**	-	-	-	-	-	**143**
Big Love and pastoral Funds	**23,821**	**338**	**(13,659)**	**8,463**	-	-	**18,963**
Investment Reserve	**1,019,388**	-	-	-	**345,776**	-	**1,365,164**
	10,360,651	**1,285,522**	**(1,990,118)**	**(8,463)**	**345,776**	**3,159**	**9,996,527**

21. Designated funds Continued

	Balance at 1 April 2022	Income	Expenditure	Transfers	Net losses on investments	Other gains and losses	Balance at 31 March 2023
	£	£	£	£	£	£	£
Designated Funds	6,923,606	1,525,794	(783,716)	(280,187)	-	-	7,385,497
Solving Kids' Cancer Children's Reserve Fund	600,812	-	(9,400)	28,019	-	-	619,431
Solving Kids' Cancer Research Fund	959,004	101,466	61,150	196,130	-	(6,778)	1,310,972
Family Support Fund	29,123	3,000	(30,724)	-	-	-	1,399
Covid-19 Fund	143	-	-	-	-	,-	143
Big Love and pastoral Funds	5,927	615	(10,740)	28,019	-	-	23,821
Designated general	16,839	(16,839)	-	-	-		-
Investment Reserve	1,204,068	-	-	-	(184,680)	-	1,019,388
	9,739,522	1,614,036	(773,430)	(28,019)	(184,680)	(6,778)	10,360,651

Designated funds are funds which have been allocated by the trustees out of undesignated general funds to specific appeals for the treatment of children with neuroblastoma. In the event of a child's death, the funds will be released from designated funds. Following the end of a successful course of treatment, and a child exhibiting no evidence of disease (NED), funds will remain designated for a period of 5 years so that they are available for that child should they suffer a relapse and require further treatment, a situation which is common for neuroblastoma patients. During the year, this policy resulted in transfers of £84,627 (2023: £280,187) with 70% transferred to the designated Solving Kids' Cancer Research Fund, 10% to the designated Solving Kids' Cancer Children's Reserve Fund, 10% to designated pastoral funds and 10% to undesignated reserves.

Solving Kids' Cancer Children's Reserve Fund is money designated to;
(1) support families who are fundraising for treatment who may require additional financial support to be able to meet the deadlines for enrolment on a particular clinical trial.

(2) support children who are receiving treatment abroad but for whom additional unanticipated medical expenses are incurred. During the year £8,463 was transferred from Designated funds (2023: £28,019).
(3) provide pastoral funding to families through SKC grant programmes (currently includes Big Love Fund and Clinical Trial travel).
(4) any spend specifically approved by the Board which directly benefits families looking to access treatment.

Solving Kids' Cancer Research Fund is a designated fund where monies are not currently awarded to any specific research project, but nonetheless earmarked to support research. During the year, £59,238 was transferred from Designated Funds (2023: £196,130).

Family Support Fund is designated to the activities of the family support team.

COVID-19 fund is designated to the granting of funds to families of children with Neuroblastoma who have suffered a loss of income or increase in costs as a result of the diagnosis. It was initially for those affected by the need to shield during COVID-19.

Big Love and pastoral Funds is designated to the granting of pastoral funds to support a child or young person's physical or emotional welfare and to support families in bereavement. During the year £8,463 was transferred from Designated funds (2023: £28,019).

Designated general is a general fund to hold designated income prior to allocation against an individual fund for example whilst awaiting gift aid allocation.

Investment Reserve represents the movement in fair value on investments since acquisition.

22. Undesignated funds

	Balance at 1 April 2023	Income	Expenditure	Transfers	Other gains and losses	Balance at 31 March 2024
	£	£	£			£
Undesignated funds	**959,981**	**1,003,793**	**(1,101,031)**	**8,463**	**(22,547)**	**848,659**

	Balance at 1 April 2022	Income	Expenditure	Transfers	Other gains and losses	Balance at 31 March 2023
	£	£	£			£
Undesignated funds	984,377	760,051	(862,928)	28,019	50,462	959,981

23. Analysis of net assets between funds

Fund balances at 31 March 2024 are represented by:

	Undesignated funds	Designated funds	Restricted funds	Total funds 2024
	£	£	£	£
Tangible fixed assets	**6,722**	-	-	**6,722**
Investments	-	**3,865,164**	-	**3,865,164**
Cash at bank and in hand	**1,289,255**	**7,868,586**	**2,238,979**	**11,396,820**
Other net current (liabilities)/assets	**(447,318)**	**(432,352)**	**(97,934)**	**(977,604)**
Creditors falling due in more than one year	-	**(1,304,871)**	**(76,995)**	**(1,381,866)**
	848,659	**9,996,527**	**2,064,050**	**12,909,236**

Fund balances at 31 March 2023 are represented by:

	Undesignated funds	Designated funds	Restricted funds	Total funds 2023
	£	£	£	£
Tangible fixed assets	8,976	-	-	8,976
Investments	-	3,519,388	-	3,519,388
Cash at bank and in hand	1,523,780	7,555,004	2,205,695	11,284,479
Other net current (liabilities)/assets	(572,775)	(271,763)	(76,591)	(921,129)
Creditors falling due in more than one year	-	(441,978)	(116,416)	(558,394)
	959,981	10,360,651	2,012,688	13,333,320

24. Company limited by guarantee

The charity is a company limited by guarantee and has no share capital. The liability of each member in the event of winding up is £10.

25. Taxation

The charity is exempt from tax on income and gains to the extent that these are applied to its charitable objects.

Notes to the financial statements Continued

26. Related party transactions

The key management personnel of the charity for the year comprised the Trustees, Chief Executive Officer and the Heads of Departments. The total employee benefits of the key management personnel were £369,170 (2023: £301,390).

The trustees did not receive any remuneration or other benefits during the year (2023: £nil). One trustee received reimbursement of expenses during the year of £569 relating to travel and subsistence (2023: £854 relating to memberships and subscriptions).

During the year, the charity paid £600 to Yassine Rhardoud, the husband of member of key management Claire Hislop, for moving and refurbishment costs associated with the move to the new office.

The total donations received from 2 trustees (2023: 2) during the year amounted to £2,688 (2023: £1,100).

27. Financial instruments

Financial assets measured at fair value through statement of financial activities:

	2024 **£**	2023 £
Investments	**3,865,164**	3,519,388

The income, expense, gains and losses in respect of all financial instruments are summarised below:

	2024 **£**	2023 £
Net gain / (loss) on revaluation of investments	**345,776**	(184,680)
Investment income	**108,084**	107,438

For further details about risks arising from financial instruments and the measurement basis see note 13.

28. Analysis of changes in debt

	At 1 April 2023 **£**	**Cash flows** **£**	**At 31 March 2024** **£**
Net cash			
Cash at bank and in hand	**11,284,479**	**112,341**	**11,396,820**

	At 1 April 2022	**Cash flows** **£**	**At 31 March 2023** **£**
Net Cash			
Cash at bank and in hand	10,120,041	1,164,438	11,284,479

29. Comparatives for the statement of financial activities

	Undesignated Funds £	**Designated Funds** £	**Restricted Funds** £	**Total Funds 2023** £
INCOME			-	
Donations	569,044	1,602,591	592,670	2,764,305
Trading activities	29,265	11,445	3,800	44,510
Investment income	161,742	-	20,967	182,709
TOTAL INCOME	**760,051**	**1,614,036**	**617,437**	**2,991,524**
EXPENDITURE				
Raising funds	(301,347)	(17,978)	(1,781)	(321,106)
Charitable activities	(561,581)	(755,452)	(246,712)	(1,563,745)
TOTAL EXPENDITURE	**(862,928)**	**(773,430)**	**(248,493)**	**(1,884,851)**
NET INCOME / (EXPENDITURE) BEFORE LOSSES ON INVESTMENTS	(102,877)	840,606	368,944	1,106,673
Net losses on investments	–	(184,680)	–	(184,680)
Other gains / (losses)	50,462	(6,778)	–	43,684
NET INCOME	(52,415)	649,148	368,944	965,677
Transfer between funds	28,019	(28,019)	–	–
NET MOVEMENT IN FUNDS	(24,396)	621,129	368,944	965,677
RECONCILIATION OF FUNDS				
Total funds brought forward	984,377	9,739,522	1,643,744	12,367,643
TOTAL FUNDS CARRIED FORWARD	**959,981**	**10,360,651**	**2,012,688**	**13,333,320**

Thank You

We want to say a heartfelt thanks to the following companies, people, schools, charities, foundations and trusts for their wonderful support.

Companies

Allen & Overy LLP
A&O Shearman
Anglo Stainless
Burnt Peach
Flix Interactive
GamesAid
Google
GRC World Forums
Harper Collins
Irish Solicitors Bar Association
iTech Media
Julius Baer International Ltd
Keel Toys
Laser Quest
Marks Sattins
Miniclip
Norgine
OVID Health
Pipeline Technology Centre
Party Ideas
Pitstop Productions
Privacy Culture Limited
Recordati Rare Diseases
Ritter Sport
Sanofi
Scamp and Dude
Sumo Digital
United Therapeutics
Y-mAbs Therapeutics Inc.
We Can Kick It
Workspace
US World Meds
Reach Creative Branding Ltd

Patron & Champions

Kellie Bright
Rob Brydon
Carl Cavers
Demie Risby

Parent Involvement Forum

Naomi Bentham
Leeanne Brennan
Kate Dixon
Claire Donnelly
Garrett Fitzgerald
Stewart Leaver
Naomi Shefford-Thomas
Carrie Wright

Schools

London Oratory School
Eton House School

Ambassadors & individuals

Clare and Chris Andrew
Polly Arber
Mandy Berriman
Mary Boullin
Ashley Byam
Ed Cartledge
Tony Clay
Will Cocker
Adam and Hannah Cohen
Pippa Collins
Graham Cooper
Stephanie Davies
Kevin Doyle
Tom Donegan
Jack Fleming
Gurlaine Kur Garcha
Roger Griffiths
Liam Gurney
Rob Hancock
Ruben Hage
Richard Hage
Christina Haralambous
Patrick Harney
Tom Hartley Jnr
Shirley Hepworth
Sirine Jahangir
Liliana Jackson
Nicholas Jackson
Russell Jackson
Prof Pam Kearns
Adelaide Lane
Stewart and Cassie Leaver
Chris Lee
Kim Leadbeater MP
Gavin Lindberg
Cameron Miller
Darren Mills
Louis Moorhouse
Louise Murphy
Robson O'Reardon
Cliona O'Tuama
Polly Ord
Lara Polati
Jude Sibley
James Speakman
Nick Streeter
Ali Timmons
Iulia and Padmesh Thuraisingham
Ioannis Topsakalidis
Mark Ward
Grace White
Colleen White
Katy Yeandle

EastEnders choir:

Zaraah Abrahams
Isobel Allan
Gareth Ambrose
Delroy Atkinson
Renee Baker
Emma Barton
Joanna Bayliss
Kellie Bright
Natalie Cassidy
Navin Chowdhry
Charlotte Christoforon
Juhaim Rasul Choudhury
Tia Daby
Ellie Dadd
Sarah Edwards Knight
Dee Helier
Margaret Jarvie-Smith
Aaliyah James
Lawrie Jordan
Katy Karger
Sophie Khen Levy
Jaden Ladega
Fiona Martin
Ruth Mandel
Matthew Morrison
Clair Norris
Jacqueline Osborne
Maria Paraskeva
Diane Parish
Emma Perry
Heather Peace
Hannah Pigott
Julia Sawkins
Simon Naylor
Harriet Thorpe
Gilly Taylforth
Lacey Turner
Rudolph Walker
Gillian Wright
Melissa Wright

Charities, foundations & trusts

Anticancer Fund
Band of Parents
Cancer Awareness Trust / Cancer Platform
GamesAid
Joining Against Cancer in Kids (J-A-C-K)
Joseph's Smile
Kindred Foundation
Neuroblastoma UK
Rupert's Revenge
Solving Kids' Cancer US
SpecialEffect
St. George's Society of New York
The Evan Foundation
The Merryn Lacy Trust
Zoe4Life

Family & named funds

Alfie's Wishes
Hannah's Heroes
Oscar Knox Fund
Smiles for Stanley
The Isla Caton Fund

Hero Awards 2023 recipients

Clare Andrew
Andy Biddle, Chris Haigh, Katie Derry, Sarah Gibbon and Roberttown Community
Clare Churchman
Jessie Collins
Jayne Delaney
Gabriella Flynn
Wendy Gardner
Chris Lee
Darren Mills
Phoebe McCluskey
Robson O'Reardon
Leah Walton
We Can Kick It, received by Adrian Conoboy MBE
Wendy Gardner

Scientific Advisory Board Members

Dr Steve Dubois
Dr Julia Glade-Bender
Dr Juliet Gray
Dr Meredith Irwin
Prof John Maris (Vice-Chair)
Dr Lucas Moreno
Dr Julie Park
Prof Andy Pearson (Chair)
Prof Michel Zwaan

Our Patrons

Rob Brydon

Rob, one of the UK's most celebrated performers, joined as our first charity Patron on 2020. He has a personal connection to Solving Kids' Cancer UK, having supported out Trustee, Max White and his family, when their son Felix was diagnosed with neuroblastoma in 2009 at the age of four..

Carl Cavers

Carl is chief executive Officer of Sumo Group and first reached out to Solving Kids' Cancer UK following our call to the gaming community to make a seemingly impossible wish come true for an inspirational young man, Luke. Carl and Sumo Group continue to provide incredible support and opportunities for Solving Kids' Cancer UK. Carl joined the Trustee Board in Sept 2024.

Kellie Bright

Kellie has been a prominent part of the BBC's Eastenders cast for 10 years. After visiting her cousin on the oncology ward at University College Hospital in London, she was introduced to a Solving Kid's Cancer UK member of staff who told her about the charity's work. Kellie rallied 22 of her fellow Eastenders cast members to sing and meet families affected by childhood cancer at our Christmas Carol Concert and we're delighted that she has joined the charity as a Patron.

Solving Kids' Cancer UK

Solving Kids' Cancer UK is a registered charity. We receive very little public funding for our work. Thanks to supporters and philanthropic partnerships we've made progress over the years. But there is still so much more to do to ensure a future where no child dies of childhood cancer neuroblastoma or suffers due to the treatment they receive.

The support you give will make the difference to the lives of children and families affected by childhood cancer. For more information on how you can support and to donate;

Visit: solvingkidscancer.org.uk
Call: 020 7284 0800
Email: fundraising@solvingkidscancer.org.uk

Or donate directly here;

Solving Kids' Cancer UK
Unit 02-03, Salisbury House, 29 Finsbury Circus, London EC2M 7AQ
Email: info@solvingkidscancer.org.uk
Telephone: 020 7284 0800

- @SKC_UK
- SolvingKidsCancer365
- skc365
- Solving Kids' Cancer UK

Registered with FUNDRAISING REGULATOR